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ABSTRACT 
 
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated channels 
that contain combinations of α and β subunits (heteromeric) or only five α subunits 
(homomeric). To date, 12 subunits have been cloned. Although different types of 
neuronal nAChRs are expected to occur in vivo, most structure-activity relationship 
studies have been carried out for just a few neuronal subtypes. Clinical and basic 
research has shown that cholinergic receptors play a role in several disorders of 
the nervous system such as chronic pain, Alzheimer’s disease and addiction to 
nicotine, alcohol and drugs. Unfortunately, the lack of selective modulators for 
each subtype of nAChR makes their pharmacological characterization difficult, 
which has slowed the development of therapeutic nAChR modulators with high 
selectivity and absence of off-target side effects. 
 
Animal venoms have proven to be an excellent natural source of bioactive 
molecules with activity against ion channels. Venoms from different snakes and in 
particular molluscs of the Conus genus have been an important source of 
modulators of cholinergic receptors. However, spider and scorpion venoms have 
been studied less extensively and there are only two examples of cholinergic 
receptor modulators reported from arachnid venom. Thus, the primary goal of this 
thesis was to identify novel modulators of the human ganglionic α3* nAChR 
(where the asterisk indicates that β subunits form part of the heteropentameric 
receptor) and the homomeric neuronal α7 nAChR using spider and scorpion 
venoms.  
 
“Hit” venoms from a selection of “modern” and “primitive” spiders were identified 
via high-throughput screens against the α3* and α7 nAChRs endogenously 
expressed in SH-SY5Y cells. A total of 71 spider venoms were screened, with 
representatives from nine different taxonomic families. The resulting data showed 
that 91% of the venoms presented some activity against the nAChR subtypes 
tested and most of these were non-selective blockers of the α3* and α7 subtypes. 
Toxins directed against vertebrate nAChRs likely evolved through frequent 
interactions between spiders and small vertebrate predators. Our data revealed 
that nAChR agonists are likely to be present in venom of the “primitive” spiders 
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and therefore were probably basally recruited in spider venom. In summary, the 
screening of spider venoms against vertebrate cholinergic receptors provided 
information about the origin and evolution of toxins against vertebrate receptors.  
 
The search for nAChR modulators was extended to scorpion venoms that are 
recognized as sources of toxins that affect primarily the properties of voltage-gated 
sodium and potassium channels. In this work, venoms from Androctonus australis, 
Androctonus crassicauda, Leirurus quinquestriatus and Grosphus grandidieri 
(Buthidae) and Heterometus spinnifer (Scorpionidae) were screened against the 
α3* and α7 nAChRs using SH-SY5Y cells. The venom of Heterometrus spinnifer 
was found to contain an agonistic compound. Activity guided-fractionation allowed 
isolation of the “hit” toxin, and it was identified by high-resolution mass 
spectrometry as senecioylcholine. This non-peptide toxin has not previously been 
identified in arachnids but it was previously isolated from some marine gastropods 
(Muricidae). It shows high toxicity against vertebrates. Thus, this non-peptide toxin 
is likely to function in defence against vertebrate predators. 
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CHAPTER 1 — INTRODUCTION 
 
Recent studies indicate that imbalance of the cholinergic system in human brain 
via nicotinic acetylcholine receptors (nAChRs) are linked to various neurological 
disorders (AhnAllen, 2012; Chu, 2005; Nides, 2006; Tregellas, 2011; Yu, 1996) 
while mutations in the nAChR can lead to frontal lobe epilepsy (for a review see 
(Steilein, 2001)). These findings have prompted research into the development of 
drugs that target neuronal cholinergic receptors. Nevertheless, most of the 
chemical components under trial lack selectivity, or hardly improve the medical 
condition (for reviews, see (Arneric, 2007; Jensen, 2005; Pammolli, 2011)). The 
discovery of new therapeutic agents is currently a challenge because of the 
complex arrangement of subunits of neuronal cholinergic receptors expressed in 
human brain (Gotti, 2007) and the fact that their roles under physiological and 
pathological conditions are not fully understood (for a review, see (Tuesta, 2011)). 
 
To facilitate studies of the pharmacology of nAChRs, a search for new nAChR 
modulators in spider and scorpion venoms was carried out using a high-
throughput FLIPR assay to rapidly identify “hit” venoms. The probability of finding 
native cholinergic modulators was expected to be high because arachnid venoms 
are estimated to contain about 1 million different components, and even though 
less than 0.01% of these molecules have been studied (for reviews, see 
(Escoubas, 2006b; King, 2014; King and Coaker, 2014; King and Hardy, 2013), 
many of them are peptidic toxins that act on diverse types of ionic channels 
(Meves, 1984; Quintero-Hernandez, 2013; Shahbazzadeh, 2007; Xie, 2012).  
 
This chapter provides a review of what is known about the molecular structure of 
nAChRs and their physiological functions in vertebrates and invertebrates. 
Furthermore, I review the use of animal toxins as research tools to characterize 
nAChRs, as well as their roles in the development of therapeutic drugs and 
bioinsecticides. 
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1.1  NICOTINIC ACETYLCHOLINE RECEPTORS 
 
1.1.1  Homopentameric/heteropentameric architecture of neuronal nAChRs 
 
nAChRs are members of the pentameric Cys-loop ligand-gated ion channel 
superfamily that are activated by the neurotransmitter acetylcholine (ACh) (for a 
review, see (Unwin, 2005)). Our current knowledge of the molecular structure of 
neuronal nAChRs began with determination of the N-terminal sequence of the 
nAChR isolated from the electric organ of the marbled ray Torpedo marmorata, 
followed by the cloning of its subunits. These subunits were subsequently shown 
to be closely related to cDNAs cloned from mammals that encoded 17 structurally 
homologous subunits, denoted α1–α10, β1–β4, γ, δ and ε. Each subunit 
comprises four α-helical transmembrane regions (M1–M4), of which M1-M3 are 
conserved and M4 has a variable extracellular C-terminal sequence; a conserved 
large N-terminal extracellular domain (ECD) of approximately 200 amino acid 
residues; a short intracellular C-terminal tail (see Figure 1.1A); and a variable 
cytoplasmic domain between the transmembrane regions M3 and M4 (Unwin, 
2005). In addition, all subunits contain in the first extracellular domain a cysteine-
loop (Cys–loop) that consists of a pair of cysteines, and in the case of mammals, 
the Cys-Cys pair is separated by 13 residues. This structural template describes 
the molecular backbone of different types of nAChRs. 
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Figure 1.1. General architecture of pentameric acetylcholine receptors. 
(A) Ribbon representation of the three-dimensional structure of the pentameric 
nAChR from Torpedo marmorata determined using cryo-electron microscopy 
(Unwin, 2005). The three domains are indicated: extracellular domain (ECD), 
transmembrane domain and intracellular domain (ICD). The illustration was 
modified from the original in the review by Molgó et al. (Molgó, 2013). (B) 
Schematic representation of the arrangement of a heteromeric nAChR. The 
subtype α3β4 (left) contains two α3 and three β4 subunits. The heteromeric 
subtype has two binding sites for ACh (black circles) between α3 and β4 subunits. 
Homomeric subtypes like α7 (right) contains five identical subunits, and they have 
five bindings sites for ACh (black circles). The illustration was adapted from a 
review by Changeux (Changeux, 2010). 
 
 
According to their localization and subunit composition, nAChRs are classified into 
two types, the so-called muscle-type nAChRs and neuronal nAChRs. Muscle-type 
nAChRs contain five classes of subunits denoted α1, β1, δ, and either γ or ε, which 
are arranged in a circular order of barrel-like staves around a central channel in 
the muscle sarcolemma, and with a stoichiometry of 2:1:1:1, which corresponds to 
two α1 subunits plus β1, δ, and γ/ε subunits (Miyazawa, 1999; Unwin, 1993). 
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In contrast to the muscle-type nAChRs, the neuronal-type receptors are more 
diverse. Neuronal nAChRs are encoded by nine α (α2–α7, α9, α8, α10) and three 
β (β2–β4) subunit genes. In the case of sensory and neuronal mammalian tissues, 
eleven subunits have been cloned, which are α2–α7, α9, α10, and β2–β4, but a 
homologue of the avian α8 subunit has not been described (reviewed in 
(Albuquerque, 2009; Nicke, 2004)). Neuronal nAChRs also contain five subunits 
that form a functional receptor via combinations of different α and β subunits 
(heteropentamers), such as α3β2 and α4β2. The ACh binding site is located at the 
interface between an α subunit and an adjacent β subunit (see Figure 1.1B). Also, 
a third subunit can be included in the receptor (α4)2(β2)2α5. In addition, the 
pentamers can consist of only α subunits, such as homopentamers of α7, α9 or 
α10 (Cooper, 1991); in these subtypes,  the ACh binding site is located between α 
subunits (see Figure 1B). 
 
The molecular architecture of heteropentamers and homopentamers is similar 
(see Figure 1.1B). Nevertheless, each subtype differs in function (Elgoyhen, 2001; 
Zhou, 2003). If novel and selective modulators for heteropentameric and 
homopentameric nAChRs were available some relevant questions in terms of the 
functional characterization of neuronal nAChRs could be answered. For example, 
the α6 and β3 subunits are co-expressed in brain areas such as the substantia 
nigra and the ventral tegmental area (Quik and McIntosh, 2006) which leads to two 
questions: firstly, why are these subunits co-expressed only in these areas of the 
brain, and secondly, is co-expression of these subunits related to the 
symptomatology of Parkinson’s disease or addiction to nicotine. 
 
1.1.2  The use of toxins to elucidate the molecular architecture of nAChRs 
 
Toxins derived from animal venoms have been a valuable source of 
pharmacological tools for studying structure-activity relationships of nAChRs. For 
example, the muscle-type nAChR was characterized for the first time by Changeux 
and colleagues in 1970 thanks to the use of α-bungarotoxin, which was purified 
from the venom of an elapid snake (Bungarus multicinctus), on membrane 
preparations derived from the electric organ of the eel Electrophorus electricus 
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(Changeux, 1970). In addition, the proposed binding site for ACh in nicotinic 
receptors, which lies in a cleft at the interface between the subunits, was 
determined from x-ray crystallographic structures of the acetylcholine binding 
protein (AChBP), a homolog of nAChRs, in complex with a variety of ligands  (for a 
review, see (Tsetlin and Hucho, 2009)). AChBP is a soluble protein that shares 
sequence similarity to the ligand-binding site of α1 or α7 nAChRs. Following its 
discovery, several crystal structures have been determined of the complex formed 
AChBP and various α-conotoxins (see Figure 1.2A,B). For instance, co-
crystallization of the complexes formed between AChBP and the α-conotoxins IMI 
and PnIA revealed that these peptide toxins bind at a similar spatial position in the 
ACh binding domain despite having divergent primary structures (see Figure 
1.2C). Moreover, it was shown that hydrophobic interactions between the ACh 
ligand- binding domain, and a conserved proline residue in both conotoxins could 
lead to a differential selectivity to nAChRs (for reviews, see (Lebbe, 2014b; Lewis, 
2012)). 
 
A large number of α-conotoxins have been used to characterise many of the 
neuronal subtypes of nAChRs (for a review, see (Lebbe, 2014b)) and structural 
studies of the α-conotoxins : nAChR interaction have been invaluable (Bourne, 
2005; Lewis, 2012). Nowadays, we can predict what amino acids residues can be 
modified to improve α-conotoxin affinity and selectivity. For example, it was shown 
that the selectivity of α-conotoxin, Lo1a from Conus longuriunis (see Figure 1.1D) 
could be switched from the neuronal α7 subtype to adult muscle-subtype nAChR 
by deleting an Asp residue from its C-terminus (Lebbe, 2014a). An α-conotoxin 
that can differentially target the muscle subtype over the neuronal subtype could 
be used to engineered probes for imaging studies of nAChRs in the peripheral 
nervous system. Because α marine cone snails represent the largest source of 
tools for studying vertebrate nAChRs, most of the modulators discovered to date 
are antagonists. In contrast, very few nAChRs agonists have been reported. 
Therefore, further research is needed to obtain new, subtype-selective nAChRs 
modulators that might be useful therapeutics and/or useful tools for addressing 
fundamental questions about nAChRs.  
 
	   21 
Figure 1.2 α-Conotoxins as research tools to study the strcuture and 
function of nAChRs.  
(A) Top view of the X-ray structure of the complex between Aplysia californica 
AChBP (AcAChBP) and α-conotoxin PnIA (for a review see (Armishaw, 2010)). 
Each of the five subunits is shown in a different color (orange, green, blue, red and 
cyan). (B) A single subunit of AcAChBP interacting with an α-conotoxin , with the 
C-loop is an open position (cyan). The arrow indicates the difference in 
conformation between the C-loop in the open (cyan) and closed (red) 
conformations (for more details see review (Armishaw, 2010)). (C) Co-crystal 
structures between AcAChBP (transparent image, only two subunits shown for 
clarity) and α-conotoxin ImI. Residues Arg11 and Arg7 (labelled) that are the 
primary residues on ImI that interact with AcAChBP. Figure taken from Dutertre et 
al. (Dutertre, 2007). (D) NMR solution structure of α-conotoxin Lo1A. Disulfide 
bonds are shown in yellow. Image from Lebbe et al. (Lebbe, 2014a). 
 
1.1.3  Location and physiological function of nAChRs in vertebrates and 
invertebrates 
 
In vertebrates, nAChRs are expressed in most cells of the central and peripheral 
nervous system (Albuquerque, 2009; Cooper, 1991), and in non-neuronal cells 
(Macklin, 1998; Plummer, 2005). It seems that the role of ACh and nAChRs in the 
CNS is mainly modulatory because the cholinergic signal can be excitatory or 
C D 
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inhibitory of synaptic pathways in different cerebral areas (for a review, see 
(Picciotto, 2012)). The different roles of neuronal nAChRs are made possible by 
different combinations of α and β (Gotti, 2007). To date, the function of each 
nAChR subtype in each place of expression is still not fully understood. 
 
Human imaging studies in vivo have allowed mapping of the distribution of 
nAChRs in the human brain (Kimes, 2006). Cholinergic projections are widely 
distributed in the brain. For example, neuronal nAChRs have been reported to be 
expressed in the white matter (Ding, 2004) and are likely to be involved in the 
regulation of neuronal excitability in the thalamocortical area (Bucher and 
Goaillard, 2011). Another cerebral region is the ventral tegmental area where the 
release of glutamate and dopamine are related to the reward responses generated 
by nicotine administration (Picciotto and Kenny, 2013). It contains GABAergic, 
glutamatergic, and dopaminergic neurons; and their activities are regulated by a 
combination of α4β2* nAChRs expressed mainly in GABAergic neurons and α7 
nAChRs expressed in terminals of the glutamatergic neurons (Mansvelder, 2002). 
Neuronal nAChRs are not restricted to the postsynaptic membranes; they can also 
be expressed along the neuronal body, including axons and presynaptic terminals, 
and different subtypes of nAChRs can be co-expressed in a neuron (for a review, 
see (Picciotto, 2012)). Other cholinergic projections come from the basal forebrain 
complex to the cerebral cortex. Their terminals contain β2* nAChRs; and are 
distributed across all the cerebral cortex. Activation of the receptor lead to release 
of glutamate into the prefrontal cortex, and this mediates neuronal processes such 
as memory, attention and cue detection (Parikh, 2010). 
 
To date, it is known that in humans the distribution of nAChRs is not limited to the 
nervous system. Cholinergic receptors are expressed in human aortic endothelial 
cells (α3, α5, α7, α10, β2-4) (Wada, 2007), vascular smooth muscle cells (α2-5, 
α7, α10) and immune cells, such as human platelets (α7) (Schedel, 2010); human 
mononuclear leukocytes (α7, β2) (Albaugh, 2004), human macrophages (α1, α7, 
α10), B-lymphocytes (α3-5, α7), T-lymphocytes (α3, α4, α7, β2, β4), (for a review, 
see  (Bauwens, 2015)). The function of these receptors is linked to homeostasis of 
the inflammatory response by the cholinergic anti-inflammatory pathway. For 
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instance, when terminals of afferent fibres located in the vagus are stimulated by 
pro-inflammatory stimuli, action potentials are generated, and this causes efferent 
fibres to activate α7 expressed on macrophages by acetylcholine (for a review see 
(Egea, 2015)). In the end, α7 control the production of pro-inflammatory cytokines 
such as TNF-α and IL-6 (Zhang, 2015a) without affecting the levels of anti-
inflammatory cytokines by inhibiting NF-kB nuclear translocation and activating 
several pathways including JAK2/STA3 (Li, 2015). However, the cholinergic anti-
inflammatory pathway is not fully understood (for a review, see (Egea, 2015)). 
 
In invertebrates, nAChRs have been found in the central nervous system, where 
they mediate the excitatory synapsis of ACh. Studies of insect brain nAChRs have 
been limited because there has only been limited success with heterologous 
expression of cloned insect nAChRs (Landsdell, 2012). The main problem is that 
cholinergic currents are evoked at high concentrations of ACh and the inhibitory 
currents are usually too small to be accurately detected with electrophysiology 
experiments using Xenopus oocytes, although co-expression of insect nAChRs 
with subunits of vertebrate nAChRs has partially facilitated the expression of insect 
nAChRs (Landsdell, 2012). There are still important nAChRs from insect species 
such as honeybee Apis mellifera that are important to study to design novel and 
safe insecticides. Today, it is known insect nAChRs have similar molecular 
structure to vertebrate nAChRs. For instance, in the genome of Drosophila 
melanogaster, 10 nAChR subunit genes of nAChRs have been identified: seven 
encoded the α subtype (Dα1-7), and three corresponded to β subtype (Dβ1-3) 
(Jones, 2007). The sequences of Dα5, Dα6 and Dα7 subunits are similar to each 
other, and to α7 subunit from vertebrate nAChRs (Grauso, 2002; Jones and 
Satelle, 2009). The Dα6 subunit is the most similar to the vertebrate α7 nAChR 
(Sattelle, 2005). This similarity may allow insect brains to serve as a model system 
for studying brain insect as an alternative animal model to study the role of 
nAChRs in different pathologies. For example, more than 40% of bee brain 
consists of Kenyon cells that are the major cells of the cerebral structure, known 
as mushroom bodies or corpora pedunculata. This structure processes multiple 
sensory information derived from the antennal lobe (Akalal, 2006; McGuire, 2001). 
It was shown that neonicotinoids cause up-regulation of nAChRs (Moffat, 2015); 
	   24 
and because nAChRs can cause mitochondrial depolarization it was suggested 
the effect of these insecticides may be mediated in part by up-regulation of 
nAChRs in Kenyon cells leading to mitochondrial dysfunction, memory deficits, 
and poor navigation (Fischer, 2014; Williamson, 2013). 
 
To summarize, nAChRs engaged in different physiological functions that are 
guided by the variability of their subunits (McGehee and Role, 1995). Many efforts 
have been made to determine the role of various nAChR subtypes in the nervous 
system but most studies have focussed on the homomeric α7 and heteromeric α4 
nAChRs (Koga, 2014; Schedel, 2010; Zhou, 2003). This is reflected in the 
increasing number of drugs that target α7 and α4β2, which are under development 
for treatment of several neurological conditions. However, the lack of specific 
modulators for other nAChR subtypes makes it challenging to elucidate the role of 
each subtype under both physiological and pathological conditions. Thus, there is 
still a significant need to discover or develop highly selective modulators of 
neuronal nAChRs. 
 
1.1.4  Role of nAChRs in human disease 
 
The role of ACh is as important as their molecular target, nAChRs. It is 
synthesised by the enzyme choline acetyltransferase that transfers an acetyl 
group from acetyl-CoA to choline (Korey, 1951). Its precursor, choline, is 
endogenously produced, although it is also absorbed in the small intestine to 
reach the levels required to accomplish several functions (Zeisel and da Costa, 
2009). For example, choline is a precursor for the biosynthesis of constituents of 
plasma membrane such as phosphatidylcholine and sphingomyelin (Zeisel, 1992; 
Zeisel and da Costa, 2009). Furthermore, choline is a methyl group donor; and 
methylation is needed to regulate of expression of genes and mediate biosynthetic 
reactions (Zeisel and da Costa, 2009). A deficiency in choline has been related to 
liver damage (Buchman, 1995) and impairment of cognitive functions in older 
people (Fioravanti and Yanagi, 2005). Indeed, choline supplementation enhances 
cognitive functions in patients with schizophrenia (Knott, 2015). De-regulation of 
cholinergic function is linked to the function and expression of nAChRs. For 
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instance, chronic administration of nicotine can induce an increase in the number 
of neurons containing α4β2 nAChRs in the glutamatergic subthalamic nucleus, a 
cerebral area related to movement control (Xiao, 2015), or down-regulate the 
function of other subtype nAChRs. Below is discussed different pre-clinical and 
clinical evidence of the consequences of smoking, and links between de-regulation 
of nAChRs and major symptoms in neurodegenerative diseases. 
 
Post-mortem studies in the brain of people who suffer from Alzheimer’s and 
Parkinson’s disease (Rinne, 1991), epilepsy and schizophrenia showed that the 
density of α4β2 nAChRs is extremely low. The degeneration of cholinergic circuits 
was confirmed in human brains after the development of nicotine radioligands for 
imaging studies in vivo. For example, in vivo studies of brains of people suffering 
from Alzheimer’s disease showed a decrease of α4β2 nAChRs (Kendziorra, 
2010), and the density of nAChRs in arteries appeared to be affected as well 
(Bauwens, 2015).  
 
In patients suffering from Alzheimer’s disease and Parkinson’s disease, there is a 
notable loss of cholinergic projections into the cerebral cortex, and this has been 
considered as part of the reason for the impaired cognition observed in these 
patients, although the loss of the cortical cholinergic activity in people with 
Parkinson’s disease is notable (for a review see (Müller and Bohnen, 2013)). In 
addition, depressive symptoms in patients with Parkinson’s disease is strongly 
correlated to loss of α4β2 nAChRs in the neuronal frontal corticomesostriatal 
circuitry, while those patients with mild cognitive impairment were associated with 
low levels of α4β2 in the neuronal frontal corticobasal ganglia-limbic-cerebellar 
circuitry that includes some areas of the former circuitry (Meyer, 2009). 
Furthermore, α4β2* nAChRs are widely distributed in the brain and are not 
restricted to cholinergic or dopaminergic neurons. Thus, down-regulation of this 
heteromeric subtype may lead to dysfunction of other neuronal circuitries (Emre, 
2003). Cholinergic deregulation in the hippocampus may be associated with 
cognitive problems because this cerebral region is related to functions of learning 
and memory (Kutlu and Gould, 2015) and this correlation between dysfunction of 
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neuronal circuitry and cognitive functions is observed in various neuronal disorders 
(Drevets, 2008). 
  
nAChRs have also been identified in immune cells, and up-regulation of its activity 
in this cells has been linked to cardiovascular diseases such as atherosclerosis in 
smokers (Aicher, 2003; Egleton, 2009; Wada, 2007). Recent evidence suggests 
that the mechanism underlying this process could be activation of α7 nAChRs that 
trigger transcription of cell-adhesion proteins on endothelial cells (Alamanda, 
2012). These proteins, such as E-selectin, favour the attachment of monocytes, 
and it might lead to abnormal formation of fibrous plaques in vascular smooth 
muscle cells (Alamanda, 2012). Notably, the duration and amount of nicotine 
administered via smoking are dependent variables, and when these reach critical 
values it may facilitate the activation of numerous nAChR subtypes (Koga, 2014; 
Wada, 2007) that are linked to signalling cascades (Wada, 2007) and cause 
abnormal proliferation of neuronal and non-neuronal cells (He, 2014; Wada, 2007). 
 
1.2  MODULATORS OF NACHRS 
 
1.2.1  Modulators of nAChRs as drugs and insecticides 
 
Several clinical trials are being carried out to evaluate potential drugs that target 
nAChRs. For instance, some nicotine analogues are been used to facilitate 
quitting smoking (Rollema, 2007). Varenicline (trade name Chantix®) is currently 
being used for treatment of nicotine addiction and is a partial agonist of the α4β2 
and α3* receptors. However, varenicline also activates the α7 nAChR (Mihalak, 
2006), and it has been suggested that its mechanism of action involves is by 
modulation of several nAChRs (Bordia, 2012; Lotfipour, 2012) that contributes to 
decreasing the levels of dopamine that were previously increased by nicotine in 
the limbic system (Corrigall, 1992, 1994), thus, preventing the reward response 
induced by smoking (Mihalak, 2006; Rollema, 2007). Imaging studies in vivo of 
smokers under treatment with varenicline showed that α4β2* nAChRs are 
saturated after administration of the drug at low or high doses, and withdrawal 
effects were not detected. Unfortunately, varenicline can also cause adverse 
effects in smokers under treatment; nausea is very common and is one of the 
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primary reasons for withdrawal for treatment (Jorenby, 2006; Lam and Patel, 
2007). The side-effect is likely to be mediated by activation of ganglionic nAChRs. 
This is likely to be a common problem when using therapeutic agents that target 
multiple subtypes of nAChRs distributed across the peripheral nervous system. 
 
As mentioned previously, nAChRs are also important insecticide targets, and the 
so-called neonicotinoid insecticides that target insect nAChRs are one of the most 
successful classes of chemical insecticides. Nicotinoid insecticides are derived 
from nicotine, the major alkaloid derived from leaves and stems of the tobacco 
plant Nicotiana tabacum; nicotine is a secondary metabolite that is used by the 
plant to defend against herbivorous insects (Isman, 2006). Nicotine was used to 
control crop pests as far back as the 1700s (Siegwart, 2015) but its use was 
limited because of toxic effects on mammals and only moderate potency against 
insects. The neonicotinoids are chemically similar to nicotine but they have low 
toxicity to mammals as they were engineered to bind selectively to insect nAChRs 
(Brown, 2006). However, like the majority of chemical insecticides, most 
neonicotinoids are broadly active against a wide range of insect pests, including 
beneficial insects such bees (Déglise, 2002; Faucon, 2005). Honeybees are 
efficient pollinators that mediate plant reproduction, and therefore it would be 
highly desired to engineer insecticides that preferentially target nAChRs in insect 
pests but not beneficial insects such as pollinators or predators of the targeted 
pest. 
 
Structure-activity relationship studies are helping to guide the development of 
more selective neonicotinoid insecticides. Crystal strictures of the complex formed 
between neonicotinoids and AChBP have been used to identify rational methods 
of improving the potency and/or selectivity of particular neonicotinoids (Matsuda, 
2009). For instance, Matsuda et al. (Matsuda, 2009) compared the complex 
formed between imidacloprid, the most successful neonicotinoid, and α2β1 
nAChRs from the honeybee Apis mellifera and the green peach aphid Myzus 
persicae (Matsuda, 2009). They found a remarkable structural difference between 
the binding sites for imidacloprid in the two nAChRs, with a hidden and broader 
binding groove in the aphid nAChR compared with the bee receptor. The authors 
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suggested that linking imidacloprid to a molecular fragment that fits the groove of 
the aphid nAChR could improve the selectivity for insect pests over bees. 
 
To summarise, neonicotinoids are generally safe for humans but they can be toxic 
for small vertebrates such as birds and beneficial insects such as honeybees. 
Thus, further research is needed to develop more selective neonicotinoids with 
reduced ecological impact.  
 
1.2.2  Novel subtype-selective modulators of vertebrate nAChRs are 
required to develop accuracy pharmacological tools and potential 
therapeutic leads 
 
The selectivity of some toxins for nAChRs has facilitated the development of 
fluorescent binding probes and radioligands for use in biological sciences 
(Hannan, 2015; Schmaljohann, 2006) and nuclear medicine (Schmaljohann, 2005, 
2006), respectively. It has helped to determine the distribution of nAChRs in the 
brain of rodents (Perry, 2002; Rueter, 2006) and humans (Ding, 2004; Kimes, 
2006), including in people suffering from Alzheimer’s and Parkinson’s disease 
(Schmaljohann, 2005, 2006). For example, α-bungarotoxin a 74-residue peptide 
isolated from venom of Bungarus multicinctus, was used to affinity purify the 
nAChR from the electric organ of T. marmorata (Changeux, 1970). α-Bungarotoxin 
has also been useful for visualizing the distribution of nAChRs in the brain and the 
in the electric organ from Torpedo californica, and for identifying clones expressing 
epitopes from nAChR in Escherichia coli (Gershoni, 1987). Recently, it was shown 
that Alexa Fluor 555-labelled α-bungarotoxin labels GABAA-Rs expressed in HEK-
293 cells (Hannan, 2015), and this binding is inhibited by bicuculline, a competitive 
antagonist at GABAA-Rs, and d-tubocurarine, a non-selective nAChRs antagonist 
and a competitive antagonist at GABAA-Rs (Caputi, 2003) (see Figure 1.2A-C). 
This finding is not surprising because type-A GABAergic receptors are members of 
the pentameric Cys-loop ligand-gated ion channel family, like nAChRs (Corringer, 
2012). The selectivity of α-bungarotoxin has been used to discover new functional 
subunits of nAChRs, such as the α7 subunit of nAChRs. The vertebrate neuronal 
subunit α7 was cloned for the first time in 1990 by Couturier et al. (Couturier, 
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1990). They found the subunit formed an oligomeric channel in the membrane of 
Xenopus laevis oocytes and it was activated by nicotine and choline, and 
desensitised rapidly. This was a receptor similar to the heteropentameric nAChR 
reported previously because α-bungarotoxin blocked its activation and was able to 
bind the subunit α7. Furthermore, iodinated α-bungarotoxin has been used in 
competition studies to evaluate the specificity of radioligands towards α7 nAChRs.  
 
Nicotine radioligands are being used for imaging studies using positron emission 
tomography (PET) (for a review, see (Bauwens, 2015)). Note that radioligands are 
typically used for imaging studies at sub-therapeutic doses, and consequent safety 
rarely poses an issue. The first nicotine-based radioligand developed to label 
nAChR was [11C]-nicotine (Halldin, 1992) (see Figure 1.3E). It was synthesised at 
high purity but had low specificity when tested on human brain in vivo (Nybäck, 
1994). Other radioligands that are chemically related to nicotine are still under 
development with some promising results, such as [18F]-ZW-104 and [18F]-AZAN-α 
(for a review, see (Bauwens, 2015)) (see Figures 1.3F-G). The first probe is a 
selective ligand for the β2 subunit of nAChR and has been tested pre-clinically. 
[18F]-AZAN-α has been assayed in human studies with promising results (for a 
review, see (Bauwens, 2015)). It reached the brain in less than 20 min after 
injection, and selectively bound the α4β2 subtype (Wong, 2013). In this study the 
specificity for α4β2 was evaluated through administration of varenicline, a 
selective partial agonist of α4β2 that is used to aid smoking cessation (Rollema, 
2007). The specificity of the radiotracer for the receptor was confirmed after the 
drug blocked totally the uptake of [18F]-AZAN-α. Another radio-chemical tracer is 
[18F]-flubatine, which is an analogue of epibatidine, an alkaloid isolated from the 
skin of the frog Epipodobates tricolor (Fisher, 1994) (see Figures 1.3D,H).  
 
A-85380 is another example of a radiotracer (Kimes, 2006; Sullivan, 1996) that 
has high affinity for α4β2 nAChRs (for a review, see (Lotfipour, 2011)). It allowed 
mapping of the distribution of nAChRs in the brain of smokers and non smokers 
(Kimes, 2006). Furthermore, it has been used to confirm that expression of α4β2 
in the brain of patients with Alzheimer’s disease and dementia is significantly 
decreased, and is correlated with the degree of cognitive impairment (Colloby, 
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2010). 
 
The development of agents to be used for human brain imaging in vivo has been 
extended to design of tracers selective for the α7 subtype. Some promising results 
has been obtained even where the homomeric α7 in the human brain is found in 
low concentrations compared to α4β2. For example, [18F]-NS-10743 and [18F]-
ASEM (see Figure 1.3I-J) showed high affinity toward α7 and the distribution of 
these radioligands were found in brain areas where α7 is densely expressed, such 
as frontal cortex and hippocampus. To prove the specificity of the agents, the 
specific ligand SSR180771, which is a selective and partial agonist at human and 
rodent subtype α7, was used in competition studies. The tracers showed their 
specificity for α7 when these were displaced by SSR180771. 
 
As discussed above, part of the problem with nAChR modulators as drug leads, 
insecticides, and pharmacological tools is their lack of selectivity. This has made it 
difficult to dissect the role of nAChRs in different physiological processes (García, 
2015) as well as their role in pathophysiological processes such as cognitive 
dysfunction, depression, chronic anxiety, analgesia, inflammation and 
neurodegenerative diseases. Thus, there is still a great need to develop novel 
nAChR modulators that are both potent and selective. As discussed below, animal 
venoms have provided some of the most potent and selective nAChR modulators 
described to date, and represent a potential source of new nAChR modulators. 
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Figure 1.3. Structures of toxins and toxin derivatives that target nAChRs.  
(A) α-bungarotoxin. Image adapted from https://en.wikipedia.org/wiki/Alpha-
Bungarotoxin. (B) Bicuculline. Image from 
http://halofanon.wikia.com/wiki/Bicuculline. (C) Tubocurarine chloride. Image from 
https://en.wikipedia.org/wiki/Tubocurarine_chloride. (D) Epibatidine. (E) 11C-
nicotine. (F) [18F]-ZW-184. Image from 
http://www.iphc.cnrs.fr/dirac/productReadHit.php?id=923. (G) [18F]-AZAN-α. Image 
adapted from (Bauwens, 2015). (H) [18F]-Flubatine. Image adapted from 
(Bauwens, 2015). (I) [18F]-NS-10743. Image adapted from (Bauwens, 2015). (J) 
[18F]-ASEM. Image from Horti et al. (Horti, 2014). The pyridine and the pyrrolidine 
rings are shown in orange and green, respectively. The chemical structure of 
nicotine is similar to that from epibatidine such as pyridine rings and nitrogen 
atoms (in orange color). The tracers are shown in blue. 
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1.3  VENOM-DERIVED MODULATORS OF NACHRS 
 
1.3.1  Important role played by subtype-selective α-conotoxins in study of 
vertebrate nAChRs 
 
Venoms from marine cone snails (genus Conus) have been extensively studied, 
although scarcely 0.1% of the predicted total number of venom compounds have 
been characterized so far (Lebbe, 2014b). Conus venoms are replete with 
disulfide-bridged peptides, named conopeptides or conotoxins that target a wide 
range of voltage and ligand-gated ion channels, including nAChRs (Lebbe, 2014b; 
Lewis, 2012; McIntosh, 1999). Indeed, the venoms of marine cone snails are the 
largest natural source of potent and selective nAChR blockers (for reviews, see 
(Lewis, 2012; McIntosh, 1999)). There are at least seven families α-conotoxins 
that bind specific muscle and neuronal nAChR subtypes with high selectivity 
(Wang, 2015). α-Conotoxins are the smallest conopeptides (generally 12–20 
amino acid residues) that competitively binds to the ACh binding site of nAChRs. 
Their general framework is denoted CC-Xm-C-Xn-C, where C represents a 
cysteine residue and X corresponds to the two inter-cysteine loops that contain a 
variable region of amino acid residues. The number of amino acid residues is 
indicated as m/n and α-Conotoxins with a 3/5 loop size combination are usually 
purified from the venom of Conus species that feed on fish and are typically active 
on mammalian neuromuscular nAChRs, while other conopeptides with 4/3, 4/4, 
4/5, 4/6 and 4/7 loop combinations preferentially act on mammalian neuronal 
nAChRs (for reviews, see (Lebbe, 2014b; Lewis, 2012; Terlau and Olivera, 2004)). 
See table 1.1 below. 
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Table 1.1 Amino acid sequences of selected α-conotoxins. SI conotoxin 
from Conus striatus that targets the neuromuscular subtype cholinergic 
receptor; MII conotoxin from Conus magus that targets with heteromeric 
nAChRs with higher affinity than the homomeric subtype α7 nAChR; AuIA 
conotoxin isolated from Conus aulicus, which targets the neuronal 
heteromeric subtype α3β4. The asterisks (*) represent C-terminal amidation. 
Table adapted from (Lewis, 2012; Molgó, 2013). Loop 1 and Loop2 are the 
two intercystine loops. 
 
α-conotoxin Amino acid sequence Selectivity 
  
C Loop 1 C Loop 2 C* 
 
SI (3/5 loop) I CC NPA C GPKYS C* Muscle type 
α12βγδ 
        
MII (4/7 
loop) 
G CC SNP V C HLEHSNL C* Neuronal subtype 
α6α3β2β3>α3β2>α7 
        
AuIA (4/7 
loop) 
G CC SYP P C FATNSDY C* Neuronal subtype 
α3β4 
        
 
Several studies of the interaction between α-conotoxins and AChBP have 
contributed to our understanding of how α-conotoxins can be selective for a 
particular nAChR (Dutertre, 2007). Basically, the different electrostatic interactions 
and hydrogen bonds between aromatic residues of α-conotoxins and amino acid 
residues outside of the ACh binding pocket are found in the conotoxins that block 
nAChRs while those conotoxins with fewer interaction are more likely to be 
agonists (Dutertre, 2004). These studies have also helped develop a structural 
model of the pharmacophore of α-conotoxins. It is delimitated by the two loops 
between the cysteine residues. One is conserved and determines the binding to 
the nAChR and the second loop consists of a variable sequence that determines 
their selectivity for a particular subunit of the nAChR (for reviews, see (Lebbe, 
2014b; Lewis, 2012; Terlau and Olivera, 2004)).  
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1.3.2  nAChR modulators from other venomous animals 
 
 Snake venom is another large source of proteins and peptides that target nAChRs 
(Brahma, 2015; Utkin, 2015). The most abundant proteins described so far in 
elapid, colubrid and psammophid snakes are the three-finger toxins (3FTx) 
(Sunagar, 2013) that contain between 60 to 74 amino acid residues with molecular 
masses ranging between 6000 and 8000 Da (Manjunatha and Robin, 2010; Roly, 
2014). Most 3FTxs target nAChRs. These toxins are divided into three types 
differentiated by the number of cysteines and the inter-cysteine spacing. Type I 
and type III α-neurotoxins with eight cysteine residues target neuromuscular 
nAChRs. Type II α-neurotoxins contain an extra pair of cysteine residues which 
form an additional disulfide bond that stabilises loop 2 (Fry, 2003; Sunagar, 2013). 
This additional disulfide bond facilitates interaction with neuronal α7 and α9-10 
nAChRs, while maintaining affinity for the neuromuscular α1 nAChR (Fry, 2003). 
Another interesting group of 3FTxs are the so-called “non-conventional toxins” that 
have an additional disulfide bond that is not in the central loop II but instead in the 
N-terminal loop I (for a review see (Tsetlin, 2015)). Examples of non-conventional 
toxins that block nAChRs are candoxin from Bungarus candidus and the weak 
toxin (WTX) from Naja Kaouthia. 
 
1.3.3  Rationale for examining spider venoms as a source of novel nAChR 
modulators 
 
Spiders are very known to produce venoms that contain diverse chemical 
structures such as peptides up to 10 kDa, proteins, amino acids, and 
acylpolyamines (for a review, see (Estrada, 2007)). This complex and 
heterogeneous mixture of compounds allows spiders to prey on, and defend 
themselves against a wide range of prey and predators. The different repertoire of 
acylpolyamines appears to have evolved to allow predation of different species of 
invertebrates and small vertebrates. 
 
Acylpolyamines can selectively block ionotropic glutamate receptors from insects 
and vertebrates including mammals (for a review see (Olsen, 2011)). Because 
glutamate is the main neurotransmitter at the neuromuscular junctions in insects, 
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block of glutamatergic receptors by acylpolyamines induces paralysis (Piek, 1971; 
Piek and Njio, 1975). However, acylpolyamines toxins are also reported to 
antagonise of nAChRs (Willians, 1997). The basic backbone of acylpolyamines is 
an aromatic acyl group and the polyamine chain that form the essential part of the 
molecule (Estrada, 2007). These two features are generally present in 
acylpolyamines derived from funnel-web, trap door and tarantula spiders 
(Strømgaard, 2005). The length of the polyamine chain and the degree of 
hydrophobicity determines the affinity for nAChRs.  
 
Recently, a toxin denoted VdTX-1 was purified from the venom of the Brazilian 
theraphosid spider Vitalius dubius (Rocha-E-Silva, 2013). This component has a 
molecular weight of 728 Da and it non-competitively blocks nAChRs. Surprisingly, 
this toxin was photosensitive, which might be why this toxin, and perhaps related 
toxins in other spider venoms, was not identified in previous studies. In any case, 
there is clearly some evidence for the presence of small-molecule nAChR 
modulators in spider venoms, suggesting that these venoms should be explored 
more systematically as a potential source of novel modulators. 
 
1.4  SIGNIFICANCE AND AIMS OF THE CURRENT WORK 
 
1.4.1  Significance 
 
nAChRs are considered a key molecular target for treatment of several 
neurological and vascular disorders (Bauwens, 2015; van Enkhuizen, 2015).  Key 
knowledge about the pharmacology and distribution of nAChRs in the vertebrate 
nervous system has been achieved thanks to the use of animal toxins as research 
tools. However, we are still a long away from fully understanding of role of different 
subtypes of nAChRs in neurons and non-neuronal cells due largely to the lack of 
selective pharmacological modulators. Although animal venoms have proved to be 
an excellent source of nAChR modulators, most work has been carried out using 
venoms from snakes and cone snails, while spiders and scorpions remain largely 
unstudied as a potential source of nAChR modulators. Since spiders and 
scorpions use their venom to either hunt, or defend against, vertebrates, their 
venoms represent a potential source of compounds that can modulate the activity 
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of vertebrate nAChRs. Thus, in this thesis, I aimed to explore arachnid venoms for 
the presence of compounds that modulate the activity of vertebrate α3* and the 
neuronal α7 nAChRs.  
 
1.4.2  Aims 
 
Aim 1: Determine the taxonomic penetrance of nAChR modulators in venoms 
from the two major infraorders of spiders: the “primitive” spiders (Mygalomorphae) 
and “modern” spiders (Araneomorphae) 
 
Aim 2: Isolate and pharmacologically characterize a non-peptide nAChR 
modulator identified in venom of the scorpion “Heterometrus spinnifer”. 
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CHAPTER 2 — NACHR MODULATORS FROM SPIDER VENOMS 
 
2.1  INTRODUCTION 
 
Venomous animals use their venom to hunt prey and/or protect themselves 
against predators (Billen, 2008; Olsen, 2011). Most animal venoms are a complex 
mixture of salts, small organic compounds, peptides and proteins (Escoubas, 
2006b; Zhang, 2015b), with activity against a wide range of receptors (Inserra, 
2013; Wang, 2015) and ion channels (Billen, 2008; DeBin, 1993; Nirthanan, 2002). 
Consequently, over the past 20 years, a number of venom molecules have been 
purified which have proved useful clinically, to agronomy, or as research tools 
(Harrison, 2014; King and Coaker, 2014; King and Hardy, 2013; Lewis, 2012; 
Nicke, 2004; Windley, 2012b). 
    
One potentially rich source of compounds active against ligand-gated channels, 
which remains largely unexplored, is spider venoms (Nørager, 2014). It is 
predicted that all venoms from the estimated 100,000 extant species of spiders 
contains approximately 20 million bioactive molecules and scarcely 0.008% have 
been characterized so far (for reviews, see (Estrada, 2007; King and Coaker, 
2014; King and Hardy, 2013; Windley, 2012b)). This has been due in part to the 
small amount of venom that can be obtained from arachnids, making traditional 
biochemical characterization challenging. However, the development of high-
throughput functional assays has made it more feasible to functionally characterize 
venom from small venomous animals (for a review, see (Vetter, 2011)). 
 
There are two reasons why spider venoms were considered to be a likely possible 
source of novel molecules that target human neuronal nAChRs. Firstly, each 
venom is estimated to contain several hundred to more than a thousand molecules 
in the desired molecular weight range of between 0.1 and 10 kDa (for reviews, see 
(Escoubas, 2000, 2006a, b; Estrada, 2007; King and Hardy, 2013)), with most of 
those already isolated having been shown to predominantly act on voltage- and 
ligand-gated ion channels (for reviews, see (Escoubas, 2000, 2006a, b; King and 
Hardy, 2013)). Secondly, even though spider toxins are designed to target mainly 
insect receptors (because insects are the main prey of spiders) (Corzo, 2002; 
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Vassilevski, 2008), the similarity of invertebrate receptors to their counterparts in 
vertebrates (Lansdell, 2012) suggests that modulators of human nAChR receptors 
might be found in spider venoms.  
 
Some authors have divided spider toxins into two major groups: acylpolyamines 
and cysteine-rich peptide toxins (Liang, 2008; Vassilevski, 2009). The 
acylpolyamines were first isolated from theraphosid spiders (for reviews, see 
(Estrada, 2007; Strømgaard, 2001) and shown to cause fast paralysis in insects 
(Escoubas, 2000) but they are found in many spider venoms (Moore, 2009; 
Strømgaard and Mellor, 2004) They are known to block both ionotropic 
glutamatergic receptors (Nørager, 2014; Strømgaard and Mellor, 2004) and 
nAChR receptors in vertebrates and invertebrates (Mellor and Usherwood, 2004; 
Strømgaard, 2001). Their potential therapeutic and insecticidal use has led 
researchers to synthesise acylpolyamines (Strømgaard and Mellor, 2004) and 
study their structure-activity relationships in detail in order to improve their affinity 
for either glutamatergic (Kromann, 2002) or cholinergic receptors (Olsen, 2006). 
Recently, a small molecule of 728 Da was isolated from the venom of the 
theraphosid spider Vitalius dubius that blocked cholinergic receptors in vertebrate 
nerve-muscle preparations (Rocha-E-Silva, 2013). The structure of the molecule 
was not determined but its sensitivity to light and its small size suggests that it 
likely to be a polyamine. 
 
In addition to polyamines, other small molecules can be found in spider venoms, 
such as amino acids (GABA, glutamate, acetylcholine), adenosine triphosphate 
(ATP) and adenosine monophosphate (ADP) (for reviews, see (Estrada, 2007; 
King and Hardy, 2013; Olsen, 2006, 2011). These molecules are endogenous 
modulators of ion channels and receptors both in invertebrates and vertebrates but 
their lack of selectivity makes these molecules unsuitable as drug leads (for a 
review, see (King and Hardy, 2013)). 
 
Most spider venoms are dominated by high concentrations of small cysteine-rich 
peptides (King and Hardy, 2013). Most of these peptide toxins conform to a 
structural scaffold known as an inhibitor cysteine knot (Nicke) or "knottin" fold (for 
a review, see (King and Hardy, 2013)). Numerous spider-venom ICK peptides that 
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target ion channels and receptors have been identified in the venom of both 
mygalomorph (Ayroza, 2012; Corzo, 2008) and araneomorph (Trachsel, 2012; 
Vassilevski, 2013) spiders. In contrast, there is a small group of spiders whose 
venoms contain cytolytic peptides that consist of linear amphipathic domains (for 
reviews, see (King and Hardy, 2013; Windley, 2012a). These peptides, which are 
devoid of disulphide bridges, have been identified in venoms of araneomorph 
spiders from the families Ctenidae, Lycosidae and Oxyopidae (for reviews, see 
(King and Hardy, 2013; Kuhn-Nentwig, 2003). 
 
Apart from the discovery of huwentoxin-I (HWTX-I), which blocks vertebrate 
cholinergic transmission, from venom of the theraphosid Haplopelma schmidti 
(formerly Selenocosmia huwen Selenocosmia (now Ornithoctonus huwena) (Zhou, 
1997), there is no evidence of spider-venom peptides with effects on cholinergic 
receptors. In this work, a systematic approach was undertaken to screen 71 spider 
venoms, extracted from representative species of both “primitive” and “modern” 
spiders, for modulators of vertebrate neuronal nAChRs, using a high-throughput 
FLIPRTETRA screening approach. It was hoped the data derived from the screening 
of spider venoms would identify lead peptide toxins that could be further 
characterised as potential therapeutic agents. However, no “hit” peptide toxin 
could be identified. Nevertheless, cholinergic modulatory activity was identified in 
venoms from a number of species and this data was used to map the taxonomic 
distribution of modulators that target human neuronal nAChRs.  
 
2.2  METHODS AND MATERIALS 
 
This chapter describes the strategy followed to identify modulators of nAChRs in 
crude spider venoms using a high-throughput FLIPR assay. The protocol used for 
the high-throughput FLIPR assay was based on that described by Vetter and 
Lewis (Vetter, 2012; Vetter and Lewis, 2010). 
 
2.2.1  Tissue culture reagents 
 
RPMI (Roswell Park Memorial Institute) medium, (+)-L glutamine; DPBS 
(Dulbecco’s Phosphate Buffered Saline) without CaCl2 and MgCl2; 0.25 % 
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Trypsin/EDTA were from Gibco Life Technologies (Mulgrave, Vic, Australia). 
Fetal Bovine Serum (FBS) were from Scientific Life (Clayton, Vic, Australia). PNU-
120596 (1-(5-chloro-2,4 -dimethoxyphenyl)-3-(5-methylisoxazol-3-yl) urea) was 
from Sigma-Aldrich. FLIPRTETRA pipet tips, and Calcium-4 no-wash kit were from 
Molecular Devices (Sunnyvale, CA, USA).  
 
384-Well cell/imaging microplates (flat-well, clear-bottom black polystyrene) and 
384-Well reagent microplates (clear-well, round-bottom polypropylene) were from 
Corning® Incorporation (Corning, Lowell, MA, USA). Nicotine and choline were 
from Sigma-Aldrich (Castle Hill, New South Wales, Australia), and were prepared 
as a stock solution of 100 mM in MilliQ water. The composition of the Physiological 
Salt Solution (PSS) used in all the assays was NaCl 140 mM, glucose 11.5 mM, 
KCl 5.9 mM, MgCl2 1.4 mM, NaH2PO4 1.2 mM, NaHCO3 5 mM, CaCl2 1.8 mM, 
HEPES 10 mM, and pH adjusted at 7.4 using NaOH (Vetter 2012). 
 
2.2.2  Spider venoms 
 
Crude venoms were extracted from spiders by Dr Volker Herzig (Institute for 
Molecular Bioscience, The University of Queensland) via electrical stimulation of 
the chelicerae. Venoms were then lyophilized and stored at –20°C. Before starting 
fractionation of venoms using reverse-phase high-performance liquid 
chromatography (RP-HPLC), crude venom (1 mg) was dissolved in 5% Buffer B 
(90% CH3CN, 0.05% TFA in H2O). 
 
Crude venom from 71 spiders was used in this research (see Appendix I for the list 
of spiders whose venom was analysed for nAChR activity using the FLIPRTETRA 
system). For the FLIPR screens, four different concentrations of spider venom 
were prepared using MilliQ water as diluent. All venoms and toxins were dissolved 
in MilliQ water before running the FLIPR calcium assay.  
 
2.2.3  Cell lines and culture 
 
In this project SH-SY5Y cells were used for all FLIPR screens because they are 
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reported to endogenously express the neuronal α7 nAChR and the “ganglionic” 
nAChRs, named α3β2 and α3β4 (Dajas-Bailador, 2002). To facilitate the 
description of these heteromeric receptors, an asterisk (*) is included to denote the 
possibility of various β subunits in combinations with α3. The calcium responses 
evoked by these subtypes after stimulation with choline and PNU-120596, and 
nicotine, respectively, were characterized previously by Vetter and Lewis (Vetter 
and Lewis, 2010). 
 
SH-SY5Y human neuroblastoma cells (a kind gift from Victor Diaz, Max Planck 
Institute for Experimental Medicine, Göttingen, Germany) were maintained at 37°C 
with 5% (v/v) CO2 in RPMI medium which contained 2 mM L-glutamine and 15% 
(v/v) FBS. Cells were passaged every 3–5 days using 0.25% trypsin/EDTA at a 
dilution of 1:7. The SH-SY5Y cells were passaged a maximum of 10–20 times in 
antibiotic-free medium, prior to use for assay. The SH-SY5Y cells used in this 
project did not show irregular expression of α3* and α7 nAChRs as the control 
calcium responses, which were obtained in each high-throughput screening, were 
comparable to the control responses obtained by Vetter and Lewis (Vetter and 
Lewis, 2010) during the characterization of α7 and α3* nAChRs expressed in SH-
SY5Y cells. 
 
Two days prior to assay, a confluent culture of SH-SY5Y cells was collected by 
trypsinization and resuspended in RPMI with 15% (v/v) FBS, then 20,000 SH-
SY5Y cells per well were seed in uncoated black–walled 384-well imaging plates 
and maintained at 37°C and 5% CO2 for 48 h before running the experiment 
(Vetter and Lewis, 2010). This time is the optimum to obtain a homogenous 
monolayer of cells, thus avoiding problems associated with cellular differentiation 
and changes in the levels of endogenous expression of receptors and ion 
channels (Vetter, 2012). 
 
2.2.4  Preparation of the Calcium 4-dye 
 
A stock solution of calcium 4-dye was prepared according to the instructions of 
Molecular Devices. Briefly, 10 ml of PSS is added to the component A to make a 
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10 x concentrated stock solution, then the solution is protected from light with 
aluminium foil and stored in aliquots of 100 µL at –20°C. Aliquots can be reused, 
at least once, if refrozen at –20°C immediately post-experiment. 
 
2.2.5  High-throughput FLIPR calcium assay 
 
The FLIPR-based calcium-influx assay has been shown to be a good high-
throughput approach to identify and characterize toxins derived from animal 
venoms (Inserra, 2013; Jin, 2014; Wang, 2015). In this research project, a FLIPR-
based calcium assay was used to expedite the discovery of bioactive molecules 
from complex mixtures of spider venoms. 
 
71 spider venoms were screened using the fluorescent calcium FLIPR assay, and 
either agonistic or antagonistic function at α7 and α3* nAChRs was measured 
according to the methodology described by Vetter and Lewis (Vetter and Lewis, 
2010). Briefly, 20,000 SH-SY5Y cells per well were seeded on uncoated black–
walled-384-well walled imaging plates and maintained at 37°C and 5% CO2 for 48 
h before running the experiment. Once a 95% confluent monolayer was obtained, 
the RPMI medium was removed from the cell plate by flicking it, the cells were 
immediately loaded with Calcium 4-no-wash-dye (Molecular Devices), prepared as 
a 1 x solution in PSS as indicated above, for 30 min at 37°C and 5% CO2. A 
washing step after medium removal and after dye loading was not required as a 
no-wash calcium dye was used and all the control calcium responses elicited by 
cholinergic receptors stimulated by nicotine and choline were comparable to the 
calcium responses obtained in previous work (Vetter and Lewis, 2010). 
 
It is noteworthy that the 30 min of incubation time is optimal for dye-uptake, and 
de-esterification of the acetoxymethyl ester (AM) by endogenous esterases 
(Vetter, 2012; Vetter and Lewis, 2010). The cell preparation was always protected 
from the light during the incubation to prevent photobleaching of the fluorophore.  
 
After dye loading, the cell plate was transferred to the FLIPRTETRA fluorescence 
plate reader and a protocol test signal was executed to obtain an appropriate level 
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of fluorescent baseline that is approximately 1,000 arbitrary fluorescence units with 
a standard deviation less than 5%. In general, the excitation intensity was adjusted 
in 80% and camera gain around 150. All fluorescent calcium responses were 
recorded using a ‘two-addition’ protocol and a cooled CCD camera with excitation 
wavelength of 470–495 nm and an emission wavelength of 515–575 nm for over a 
period of 10 min. 
 
After baseline fluorescence readings were recorded every second for 5 s, variable 
amounts of crude venom (2 µg; 1 µg; 0.2 µg; 0.02 µg), venom fractions (1% of 
venom fraction in relation to 1 mg of crude venom fractionated by RP-HPLC was 
tested) or pure toxin (1% of pure toxin in relation to 1 mg of crude venom dissolved 
in MilliQ water was tested) were added to the cell plate (addition 1) and the 
calcium response was measured every second for 300 s. At the end of this time, 
cells were subsequently stimulated with nicotine (30 µM) or choline (30 µM) + 
PNU-120596 (10 µM) (addition 2), and readings continued every second for an 
additional 300 s. 
 
From the stock solution of nicotine (100 mM) and choline (100 mM), a working 
solution for each agonist was prepared at 120 µM in MilliQ water. The final 
concentration of nicotine or choline in each well of the plate that contains the SH-
SY5Y cells was 30 µM. 
 
2.2.6  Activation of α3* nAChR by nicotine 
 
The activation of the α3* nAChR by nicotine (30 µM) was measured using the 
‘two-addition’ protocol mentioned above. This protocol is described in Section 
2.2.8 and a schematic of the protocol is shown in Figure 2.1A.  
 
The reagent plate with venoms or venom fractions takes a long time to prepare 
when testing 71 venoms at different concentrations. To avoid loss of incubation 
time once cells were loaded with calcium 4-dye, the reagent plate with venoms or 
venom fractions was prepared before loading the cells. 
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After loading the SH-SY5Y cells, a fluorescent baseline was recorded for 5 s then 
PSS was added to the cells (addition 1), followed by readings each second for 
300s. During this recording time, calcium responses are not expected to be 
different from the baseline. Finally, nicotine was added (addition 2) to yield a final 
concentration in the assay of 30 µM, and the fluorescence was measured for 300 
s. At the end of this time there is a transient increase in the fluorescent calcium 
signal that corresponds to activation of α3* by the agonist nicotine. 
 
To confirm that the observed calcium responses were elicited by activation of 
nAChRs, d-tubocurarine, a non-selective blocker of nAChRs (Wenningmann and 
Dilger, 2001), was added to the SH-SY5Y cells before stimulation of α3* by 
nicotine. A stock solution of d-tubocurarine was prepared at 100 mM in MilliQ 
water and its final concentration in the assay was 30 µM. All FLIPR experiments 
included a positive control (calcium response elicited by activation of α3* by 
nicotine) and a negative control that corresponds to inhibition of these responses 
by d-tubocurarine. 
  
Figure 2.1B shows the ‘two-addition’ protocol that was employed to detect 
blockers of the calcium responses elicited by α3* nAChRs. After recording the 
fluorescent baseline for 5 s, d-tubocurarine was added to the cells (addition 1), 
followed readings each second for 300 s. No calcium responses are expected to 
occur during this time. Then, a second fluorescent baseline was read for 5 s, 
followed stimulation of α3* by nicotine (addition 2), and the fluorescent calcium 
responses were measured for another 300 s. As expected, no increase in the 
fluorescent calcium response was detected after nicotine addition. Figure 2.1D 
shows a typical recording of the inhibition of nicotine-induced calcium responses 
by d-tubocurarine.  
 
The calcium responses caused by stimulation of α3* with nicotine were generally 
smaller than those induced by choline. Furthermore, the kinetics of activation and 
inactivation were slow and they can be detected on the FLIPR assay without 
incubation of the SH-SY5Y cells with PNU-120596 (Figure 2.1C). 
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2.2.7  Activation of α7 nAChR by choline in the presence of the positive 
allosteric modulator PNU-120596 
 
The α7 nAChRs have fast kinetics of deactivation and long-lasting desensitization 
that makes it difficult to measure its activity (Lopez, 1998). An experimental 
strategy to detect its activity in SH-SY5Y cells was the addition of PNU-120596 (10 
µM) in the Calcium 4-no-wash-dye solution, followed by incubation in SH-SY5Y 
cells for 30 min at 37°C and 5% CO2 (Vetter and Lewis, 2010). The stock solution 
of PNU-120596 was prepared at 100 mM in MilliQ water and 5% (v/v) DMSO, and 
stored in aliquots of 20 µL at –20°C. Aliquots can be reused if refrozen at –20°C 
immediately post-experiment. 
 
The activation of the α7 nAChRs by choline (30 µM final concentration) was 
measured basically using the same protocol as that for the study of the α3* 
subtype. Briefly, after reading the fluorescent baseline for 5 s, PSS was added 
(addition 1) to the cells and fluorescence measurements were made for a further 
300s. Then, the agonist choline was added (addition 2) to stimulate the α7 
nAChRs, followed by fluorescence measurements for another 300 s. As expected, 
the activation of fluorescence nAChRs by choline elicited an increase in the 
fluorescent calcium response that corresponds to an increase in the concentration 
of intracellular calcium. 
 
A typical trace of increase of intracellular calcium after stimulation of α7 nAChR by 
choline is shown in Figure 2.1E. The positive allosteric modulator PNU-120596 (10 
µM) was included in assays to delay the deactivation kinetics of α7 nAChR and 
allow recording of the fluorescent Ca2+ responses (Vetter and Lewis, 2010).The 
calcium responses are mostly caused by activation of α7 when PNU and choline 
were used, although subtypes α3β2/α3β4/α5 are also activated and they were part 
of the calcium response (Vetter and Lewis, 2010). 
 
The same ‘two-addition’ protocol was used to confirm whether the calcium 
responses were elicited by α7 nAChR. Briefly, d-tubocurarine (30 µM final 
concentration) was added to the cells (addition 1) and the fluorescent calcium 
	   46 
response was read for 300 s, then choline was added (addition 2) to stimulate the 
receptor, and a final reading of the fluorescence was carried out for another 300 s. 
As expected, d-tubocurarine blocked the calcium response elicited by activation of 
α7 nAChR (Figure 2.1F). The following Section 2.2.8 provides an explanation of 
how the FLIPR assays were used to identify nAChR blockers and agonists in 
arachnid venoms. 
 
2.2.8  Identification of blockers and agonists for α3* and α7 nAChR using 
the FLIPRTETRA system 
 
A ‘two-addition’ protocol was used to detect the presence of α3* and α7 blockers 
in venoms or venom fractions. Crude venoms, venom fractions, or pure toxin were 
added first to the cells, and then the fluorescence was measured for 300 s. Those 
venoms or venom fractions that contain blockers inhibited the calcium responses 
elicited by either α3* or α7 when they were stimulated by nicotine or choline 
(addition 2), respectively.  
 
On the other hand, an agonist compound contained in the venoms or venom 
fractions caused an increase in the fluorescent calcium response before 
stimulation of the receptors by agonists (addition 2). Inhibition by d-tubocurarine 
(30 µM) was used to confirm that the observed calcium response was caused by 
activation of the receptor rather than activation of voltage-gated calcium channels 
(Sousa, 2013) or other endogenously expressed GPCRs or ion channels coupled 
to an increase in intracellular Ca2+. 
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Figure 2.1. Basic two-addition FLIPR protocol to measure calcium responses 
evoked by activation of α7 or α3* nAChRs. 
(A) Schematic of the protocol to measure calcium responses caused by activation 
of the heteromeric α3* nAChR: SH-SY5Y cells were plated onto a 384-well plate 
and loaded with calcium 4-dye after discarding the RPMI medium. The method is 
based on two additions, and control experiments were always included in every 
assay. PSS or test compound was added first to the SH-SY5Y cells and the 
fluorescence measured for 300 s, then the α3* nAChR or α7 nAChR were 
stimulated by nicotine or choline (addition 2), respectively, and the resulting 
calcium responses were measured for another 300 s. (B) Schematic of protocol 
used to confirm that the calcium responses were elicited by activation of nAChRs. 
If the calcium responses observed in (A) were elicited by activation of α3* or α7 
nAChRs they should be inhibited when d-tubocurarine (addition 1) was added 
before agonist addition, nicotine or choline, respectively. (C) Calcium responses 
recorded by the FLIPRTETRA system when α3* nAChRs were stimulated by nicotine 
(addition 2). (D) The calcium response was elicited by the activation of α3* 
because the addition of d-tubocurarine (addition 1) inhibited the calcium response 
elicited by the receptor when it was stimulated by nicotine (addition 2). (E) A 
typical calcium response elicited by activation of α7 nAChR using choline as 
agonist (addition 2). (F) The calcium response elicited by activation of subtype α7 
nAChR using choline was inhibited when d-tubocurarine was added before the 
addition of choline (addition 2). The traces of control calcium responses are an 
average of one experiment with n = 4. 
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Figure 2.2. ‘Two-addition’ FLIPR protocol used to identify nAChR agonists.  
(A) Venom was added (addition 1), then fluorescent responses were measured for 
300 s. After the cells were stimulated by nicotine or choline (addition 2), 
fluorescence measurements were continued for another 300 s. If any venom 
compound contains a blocker, the fluorescent calcium response induced by 
nicotine or choline (addition 2) will be inhibited. (B) If any venom compound 
contains an agonist there will be an increase in the fluorescence after addition 1. 
d-tubocurarine (30 µM) is added during the loading process, then venom is added 
(addition 1), if the following response is inhibited then the response was caused by 
activation of nAChRs. Finally, addition 2 occurs, followed a second reading for 300 
s. (C) 1 µg of crude venom from H. hainanum was added (addition 1) to the SH-
SY5Y cells, then the calcium fluorescent response was measured for 300 s. After 
choline was added (addition 2), the fluorescent signal was measured for other 300 
s. (D) To confirm that the increase in fluorescence after venom addition was 
caused by cholinergic activity, d-tubocurarine (30 µM) was included in the Calcium 
4-dye solution, and added to the cells. Then, the crude venom (H. hainanum) was 
added (addition 1) and the fluorescent response was measured.  The response 
was inhibited, and after choline addition (addition 2) the response remained 
inhibited. The venom was assayed in the presence of PNU-120596 (10 µM). The 
traces shown in panels (C) and (D) are averages with n = 3. 
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2.2.9  Data analysis 
 
The 71 spider venoms were tested in triplicate in at least three independent 
experiments. All data was analysed as followed: Raw fluorescence values 
obtained after venom addition were subtracted from the baseline fluorescence 
values measured during the reads between 0 and 5 s after starting the assay. In 
addition, the raw data readings obtained after stimulation of the receptors by 
nicotine or choline were subtracted from the baseline raw fluorescent values 
registered between 300 and 305 s. Then, the resulting raw fluorescent reads were 
converted to maximum calcium responses by calculating in relative light units the 
maximum values reached over the baseline reads using the ScreenWorks, 
software, version 3.1. Once the data was corrected using the baseline fluorescent 
reads, it was exported and analysed using the software Prism, version 5.0. 
 
Data are expressed as mean ± standard error of the mean (SEM) from n = 3 
independent experiments or as the mean ± SEM of the values obtained in the 
three independent experiments with a total n = 9. 
 
FLIPR data were normalized to the maximum fluorescence calcium response 
evoked by activation of α3* nAChR with nicotine (30 µM) or by activation of α7 
nAChR with choline (30 µM) and indicated as FMax (%) 
 
The fluorescent traces from the FLIPR data are reported as calcium response over 
baseline that is corrected previously by subtracting the average of the 
fluorescence elicited by the negative control (only components of buffer PPS) 
using ScreenWorks software. This eliminates the artefacts caused by buffer 
addition. 
 
2.2.10  Statistical Analyses 
 
Comparative analysis of the mean of calcium responses induced by crude venoms 
of each species on α3* and α7 nAChRs versus control responses was carried out 
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through a standard one-way ANOVA and non-parametric statistical analysis, using 
the analysis tool of GraphPad Prism®, version 5.0. 
 
2.3  RESULTS 
 
A high-throughput FLIPR screen was carried out to examine the effect of 12 
araneomorph and 59 mygalomorph venoms (see Appendix I, Table 1-2 for a list of 
species) on the calcium responses evoked by activation of α3* and α7 nAChRs 
endogenously expressed in SH-SY5Y cells. Following the initial screen, at least 
two additional screens were performed to enhance the statistical significance of 
the data, although the data for each species was highly reproducible, indicating 
that the venom composition of each species is constant across different pools of 
venom. To facilitate analysis of the 71 spider venoms, the resulting data from 
araneomorph spiders is presented first in accordance with an Araneae 
phylogenetic tree. The second group corresponds to mygalomorph spiders, and 
the data was compared in accordance with the geographical origin (state and 
country) of each species. Then, common and different elements between both 
suborders were described and later discussed (see discussion section) to 
determine possible mechanisms of evolution of modulators for vertebrate neuronal 
cholinergic receptors.  
 
2.3.1  Screening of 71 spider venoms using the high-throughput FLIPRTETRA 
system 
 
In all cases, unless specified, 2 µg of crude venom from each spider was tested 
against α3* and α7 nAChRs endogenously expressed in human SH-SY5Y cells. 
For the screening of these 71 spider venoms, a two-addition protocol was used 
(for further details see the methods section).  
 
2.3.2  Screening of venoms from “modern” spiders (Infraorder 
Araneomorphae) 
 
A phylogenetic tree of the infraorder Araneomorphae is shown in Figure 2.3, each 
superfamily is indicated on the main branches of the tree, and the name of each 
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representative spider considered in this study is indicated beside the superfamily 
name. 
 
To describe the results obtained with araneomorph spider venoms, the spiders 
were group in three groups, and are described in order of evolutionary 
appearance. The first group corresponds to the superfamily Austrochiloidea, and 
the one species from this taxon is Hickmania troglodytes, found in Tasmania. The 
spider makes and hangs beneath extensive sheet webs, and occasionally wraps 
prey after biting. The crude venom of H. troglodytes at 2 µg did not modify the 
calcium responses evoked in SH-SY5Y cells by the agonists nicotine and choline 
(Figure 2.3A). 
 
According to the tree, the superfamily Araneoidea appeared in the Cretaceous 145 
million years ago after the family Austrochiloidea. Crude venoms from four 
exemplars of the superfamily Araneoidea were used in this work: Cyrtophora 
moluccensis, Eriophora transmarina, Nephila pilipes and Nephila plumipes. This is 
a large taxon that consists of approximately 29% of the spiders described so far 
(Griswold, 2005). Venom from E. transmarina and the two Nephila species 
blocked both the α3* and α7 nAChRs with high potency whereas C. moluccensis 
specifically blocked only the heteromeric α3* nAChRs (Figure 2.3A). This venom 
had no effect on the choline response (Figure 2.3B), indicating that blockers are 
likely to target mainly the α3*. In contrast, N. pilipes and N. plumipes venom had 
equally potent inhibitory effects on α3* and α7 nAChRs, see Figures 2.3A and 
2.3B, respectively. 
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Figure 2.3. Screening of venoms from “modern” spiders against human α3* 
and α7 nAChRs using a high-throughput FLIPR assay.  
The left panel shows a phylogenetic tree of the infraorder Araneomorphae. The 
name of the spider species whose venoms were used in this study is denoted next 
to the branch of each family. The tree was adapted from (Coddington and Levi, 
1991); ma = millions of years. On the right panel is shown: A) 2 µg of crude 
venoms of the twelve araneomorph spiders were assayed in the absence of PNU-
120596 (10 µM). B) 2 µg of venoms from the same araneomorph spiders were 
assayed in the presence of PNU-120596 (10 µM). Venom from H. troglodytes 
(Family Austrochiloidea) had no effect on α3* and α7 nAChRs in the absence and 
presence of PNU-120596, respectively. Venoms from E. transmarina, N. pilipes, 
and N. plumites (Superfamily araneoidea) had a potent blocking effect on α3* and 
α7 subtypes with the exception of venom from C. moluccensis that only had potent 
blocking effect on α3* nAChRs in the absence of PNU-120596. As seen on the 
phylogenetic tree (left panel), spiders from the RTA clade evolved after the 
araneoid spiders; and venoms from Sparassidae sp. (1) and (2), and Lycosidae 
sp. showed a partial blocking effect on α3* and α7 subtypes without and with 
PNU-120596, respectively, while venoms from H. jugulans, and Ancylometes sp. 
had no effect on nAChRs, although venom from V. sylvestriformis only had a 
partial blocking effect on α3* nAChRs in the absence of PNU-120596. Venom 
from M. australianus blocked completely α3* and α7 nAChRs in the absence and 
presence of PNU-120596, respectively. The data on panel A was normalized in 
relation to the maximum calcium response elicited with nicotine addition (30 µM) 
(positive control) in the absence of PNU-120596 (10 µM) and expressed in 
percentage while data from panel B was normalised in relation to the maximum 
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calcium response elicited with choline addition (30 µM) (positive control) in the 
presence of PNU-120596. The negative control corresponds to the inhibition of the 
calcium response of nAChRs by d-tubocurarine addition at 30 µM in the absence 
or presence of PNU-120596 (10 µM). The values are averages of three 
independent experiments with n = 3. Dotted lines represent the control response in 
the absence of venoms. Using the unpaired t-test, the means between the effect of 
each venom and the control response without venom were compared. The number 
of (*) indicates the degree of significance at P < 0.05 probability level. Those 
values that lack of significance do not have the symbol (*). 
 
  
The third group of spiders used herein belong to the Retrolateral Tibial Apophysis 
(RTA) clade, and venoms from six exemplars of this group were assayed. Table 
2.1 list these species and their geographic distribution. Most species are from 
Australasia, although the two ctenid species (Ancylometes sp. and Viridasius 
sylvestriformis) are from Central and South America. Of the six venoms tested, the 
two sparassid venoms (Sparassidae sp. 1 and Sparassidae sp. 2), and the one 
lycosid venom (Lycosidae sp.) showed to have a partial blocking effect on α3* and 
α7, while one sparassid venom (H. jugulans), and the two ctenid venoms had no 
effect on vertebrate α3* and α7 nAChRs, although venom from V. sylvestriformis 
had a partial blocking effect on α3*. In striking contrast, venom from the giant 
water spider Megadolomedes australianus (family Pisauridae) blocked both 
nAChR subtypes with high potency. 
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Table 2.1. Taxonomic distribution of nAChR modulators from araneomorph 
spider venoms. Two species Sparassidae sp. were assayed; the numbers 1 
and 2 indicate they were collected in two different areas in PNG. Venoms 
with high blocking effect are indicated with two symbols denoted as √√, 
while those with partial effect are indicated with one √. The green area 
indicates that other effects on the venom is not observed. 
Spider Effect on human neuronal α3* and α7 nAChRs 
 Block of α3* 
& α7 
Block of 
α3*  
No 
effect 
Location 
Infraorder Araneomorphae 
Family Austrochiloidea 
Hickmania 
troglodytes 
  √ Tasmania, Australia 
Family Araneoidea 
Cyrtophora 
moluccensis 
 √√  Gardens across South 
East and coast from 
Queensland, Northern 
and western Australia 
Eriophora 
transmarina 
√√   Gardens across 
eastern and southern 
Australia 
Nephila pilipes √√   Gardens Northern 
Australia, PNG, China, 
Japan 
Nephila plumites √√   Sydney region 
RTA Clade 
Family Sparassidae 
Heteropoda 
jugulans 
  √  Queensland, Australia 
Sparassidae sp. 
1 
√   Papua New Guinea 
Sparassidae sp. 
2 
√     Papua New Guinea 
Family Ctenidae 
Ancylometes sp.   √ Central and South 
America 
Viridasius 
sylvestriformis 
  √ Amazon, South 
America 
Family Lycosidae 
Lycosidae sp.  √   Western Australia 
Family Pisauridae 
Megadolomedes 
australianus 
√√   South Eastern 
Australia 
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2.3.3  Screening of venoms from “primitive” spiders (Infraorder 
Mygalomorphae) 
 
Mygalomorphs are the oldest group of spiders. They are known as “primitive” 
spiders because they retain some ancestral morphological features, such as 
downward pointing chelicera (Coddington and Levi, 1991). In this study, venoms 
were derived from 59 mygalomorph spiders. The infraorder Mygalomorphae is 
comprised of 15 taxonomic families (Bond, 2012), of which two were considered 
here, namely Hexathelidae (1 species) and Theraphosidae (58 species).  
 
Four mygalomorph venoms were found to contain nAChR agonists (Section 2.9.4), 
24 venoms selectively blocked α3* nAChRs (Section 2.9.5), 26 venoms inhibited 
both α3* and α7 nAChRs (Section 2.9.6), and four mygalomorph venoms were 
found to have no effect on α3* or α7 nAChRs (Section 2.9.7). Each of these four 
groups is discussed in the following sections. 
 
2.3.4  Identification of α7/α3* nAChR agonists in the venom of theraphosid 
spiders 
 
The two-addition protocol was used to identify potential agonists of vertebrate 
nAChRs. Addition of venom (1 or 2 µg per well) from Haplopelma hainanum, 
Pamphobeteus sp., Sericopelma rubronites and Xenesthis sp. caused an 
increased calcium response in the FLIPR assay both in the absence and presence 
of PNU (Table 2.2). Based in a previous FLIPR assay performed by Dr Vetter  
(data not showed), the fluorescent responses evoked by 1 µg of venom from H. 
hainanum, Pamphobeteus sp., Sericopelma rubronites and in the absence of PNU 
were not abolished with addition of d-tubocurarine, indicating that these venoms 
lack of agonists of α3* nAChRs. Interestingly, the same venoms at 1 µg were 
potentiated in the presence of PNU, although were no assayed in the presence of 
d-tubocurarine (data not showed). Based on these previous results, I evaluated if 
the calcium responses evoked for the same venoms at 1 µg and in the presence 
of PNU were related to activation of the α7 nAChRs (Table 2.3). The venom 
responses from H. hainanum, Pamphobeteus sp., S. rubronites, and Xenesthis sp. 
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were assayed with the previous addition of d-tubocurarine (Figure 2.4A-D). The 
traces derived from the FLIPRTETRA system are presented to show the strategy 
used to identify agonists in these venoms. After crude venom addition (addition 1) 
at 1 µg, there was an increase of the calcium response that was extinguished at 
the end of the 300 s (Figure 2.4B-D) although the venom from H. hainanum 
caused an increase of the fluorescence that was sustained during this period of 
time (0–300 s) (Figure 2.4A). Then, after choline addition (addition 2), the calcium 
response was not different from that evoked by stimulation of the α7 nAChRs by 
choline (positive control) (Figure 2.4B-D). Interestingly, venom from H. hainanum 
caused complete inhibition of the calcium response evoked by choline stimulation 
of the α7 nAChR (see Figure 2.4A).  A further analysis was not carried out to 
determine if the differences of calcium responses in the presence of PNU and 
addition of d-tubocurarine were statistically significant due to the limitation of 
amount of these venoms, although the venom from H. hainanum is likely to have 
an agonist compound. 
  
	   57 
 
 
Figure 2.4. Agonism of human nAChRs by theraphosid venoms.  
All traces are averages of the maximum calcium responses over baseline (with n = 
3) elicited by crude venom from (A) Haplopelma hainanum, (B) Pamphobeteus 
sp., (C) Sericopelma rubronites, and (D) Xenesthis sp.. All responses elicited 
between 5 s and 300 s are caused by venom addition. The responses after choline 
addition were measured between 300 s and 600 s. All crude venoms were tested 
at 1 µg/well in the presence of PNU-120596 (10 µM). Dotted lines of each graphic 
correspond to averages of calcium responses over baseline (with n=3) elicited by 
the venoms in the presence of d-tubocurarine (30 µM) and PNU-120596 (10 µM). 
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Table 2.2. Apparent agonistic effect caused by venoms from four 
theraphosid spiders. After venom addition, the fluorescent calcium 
responses evoked by nAChRs in the absence or presence of PNU were 
converter into area under curve using ScreenWorks software, version 3.1. 
The values are averages of three independent experiments with n = 3. The 
mean of the control nicotine response was 509 ± 50.40 while the control 
calcium response elicited by choline was 1088 ± 38.31 
Spider Calcium response 
over baseline after 
venom addition at 
2 µg  
Calcium response over 
baseline after venom addition 
at 2 µg when PNU-120596 (10 
µM) was included in the assay  
Haplopelma 
hainanum 
345.6 ± 136 822.2 ± 127 
Pamphobeteus sp. 542.2 ± 164.2 517 ± 179 
Sericopelma 
rubronites 
241.1 ± 101.5 696 ± 137 
Xenesthis sp. 325.5 ± 151.4 678.8 ± 80 
 
 
Table 2.3. Mygalomorph spiders with venoms that are likely to contain 
agonists of α7 nAChRs. N.D indicates the effect was not determined and a 
further analysis is required to confirm that the venom effect is via activation 
of α7 nAChRs in the presence of PNU. 
 Location and affect on human α7 nAChRs 
Spider Agonistic effect Location 
Haplopelma hainanum √ Southern China and 
Vietnam 
Pamphobeteus (platyomma) 
sp. (F) 
N.D Ecuador 
Sericopelma rubronites (F) N.D Panama 
Xenesthis sp. (F) “white 
colour” 
N.D Colombia 
  
 
2.3.5  Venoms that selectively inhibit vertebrate α3* nAChRs 
 
24 theraphosid venoms were found to selectively block human α3* nAChRs 
(Figure 2.5A). The 24 species are listed in Table 2.4 along with their geographic 
distribution. These venoms did not have a substantial effect on calcium responses 
in the FLIPR assay when PNU-120596 was included (Figure 2.5B). 
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Figure 2.5. Theraphosid spider venoms that preferentially block α3 nAChRs.  
First screening of venom from “primitive” spiders against human α3* and α7 
nAChRs was carried out by using a high-throughout calcium assay. The calcium 
responses elicited by crude venom was calculated as the area under fluorescence 
curve normalized to the maximum α3* response evoked by nicotine (A) or 
stimulation of α7 by choline (B). Each value corresponds to averages of 
normalized calcium responses over baseline of at least three independent 
experiments and n = 3. All venoms were tested at 2 µg/well, in the absence (A) 
and presence (B) of PNU-120596. For a species identification see Table 2.4. 
Dotted lines represent the control response in the absence of venoms. On graphic 
A and B, the control responses corresponds to stimulation of α3* with nicotine (30 
µM), and α7 choline (30 µM), respectively. Using one-way ANOVA, the means 
between each venom and the control responses (nicotine response were 
compared). The number of (*) indicates the degree of significance at P < 0.05 
probability level. Those values that lack of significance do not have the symbol (*). 
 
 
Table 2.4. Theraphosid spiders with venoms that selectively block α3* 
nAChRs.  
Species with characteristic colors are indicated. (M) and (F) refer to gender. 
The numbers beside the name of each theraphosid spider indicates that they 
are individuals from the same species, although were collected from distinct 
localities. 
Number Theraphosid Geographic distribution 
1-A Avicularia metallica (F) 
Guyana (coast), Suriname 
(coast) 
2-B Avicularia ulrichea (F) All Brazil 
3-C Avicularia sp. 1  (M) “purple” Peru-Amazonas 
4-D Coremiocnemis tropix Australia 
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5-E Chilobrachys sp. 1 Malaysia-Penang island 
6-F Grammostola grossa 8 (F) 
Pampas from Argentina and 
Paraguay. Brazil south and 
north of Paraguay 
7-G Grammostola iheringi (M) Brazilian south, Entre Rios 
8-H 
Euathlus sp. 1  (F) 
“green” Chile 
9-1 Euathlus sp. 2  (F) “red” Chile 
10-J Euathlus vulpinus (F) “crème” Chile highland 
11-K Orphnaecus 
philippinus 
Philippines 
12-L Orphnaecus sp. Philippines-Paqnai-island 
13-M Paraphysa scrofa (F) Chile 
14-N Pelinobius muticus West Papua New-Guinea (PNG) 
15-O Poecilotheria striatus Sri Lanka, India 
16-P Pterinuchilus murinus 
Central, Eastern, Southern 
Africa 
17-Q Selenocosmia crassipes 
Australia-East Coast 
Queensland 
18-R Selenocosmia effera East PNG 
19-S Selenocosmia sp. 1 PNG 
20-T Selenocosmia sp. 2 PNG 
21-U Selenotholus foelschei Australia 
22-V Thrixopelma cyaneolum (F) Peru 
23-W Thrixopelma sp. (F) Peru – Cajamarca 
24-X Thrixopelma 
lagunas sp. (F) 
Peru – Lagunas 
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2.3.6  Venoms that non-selectively block both α3* and α7 nAChRs 
 
26 theraphosid venoms were found to non-selectively block both α3* (Figure 2.6A) 
and α7 nAChRs (Figure 2.6B). The 26 species from which these venoms were 
obtained are listed in Table 2.5 along with their geographic distribution.  
 
 
 
Figure 2.6. Many theraphosid venoms non-selectively block both α3* and α7 
nAChRs. 
Normalised calcium responses obtained from FLIPR screen of venoms in the 
absence (A) and presence (B) of PNU-120596. Each value corresponds to 
averages of normalized calcium responses over baseline of at least three 
independent experiments and n = 3. For a list of species see Table 2.5. Dotted 
lines represent the control response in the absence of venoms. On graphic A and 
B, the control responses corresponds to stimulation of α3* with nicotine (30 µM), 
and α7 choline (30 µM), respectively. Using one-way ANOVA, the means between 
each venom and the control responses (nicotine response were compared). The 
number of (*) indicates the degree of significance at P < 0.05 probability level. 
Those values that lack of significance do not have the symbol (*). 
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Table 2.5. Theraphosid spiders with venoms that non-selectively block both 
α3* and α7 nAChRs. (M) and (F) refer to gender. The numbers beside the 
name of each theraphosid spider indicates that they are individuals from the 
same species, although were collected from distinct localities. 
Numb
er Theraphosid species Location 
1 Acanthoscurria cf insubtilis (F) Peru, Bolivia 
2 Ceratogyrus bechunanicus 
Namibia, Zimbabwe, 
Mozambique, South 
Africa 
3 Ceratogyrus ezendami Mozambique 
4 Ceratogyrus marshalli Zimbabwe, Mozambique 
5 Chilobrachys sp. 2 North India-Meghalaya (State) 
6 Eupalaestrus campestratus (F) 
Argentina, Brazil, 
Paraguay 
7 Ephebopus uatuman (F) 
Argentina, Brazil, 
Paraguay 
8 Grammostola porteri (F) All Chilean coast 
9 Grammostola rosea (M) Bolivia, Argentina, and all Chilean coast  
10 Grammostola sp. 1 (F)  (Chilean North) 
11 Grammostola sp. 2  (F) Concepcion, Chile 
12 Grammostola sp.3  (F) Maule River, Chile 
13 Holothele sp.1  (F)  Carabobo, Colombia 
14 Holothele sp. 2 (F)  Peru 
15 Idiothele nigrofulva South Africa 
16 Lasiodorides striatus (F) Brazil 
17 Lasiodora striatipes (F) Brazil 
18 Nhandu chromatus 5 (F) Savannahs from Brazil and Paraguay 
19 Nhandu tripepii (M) State Para, Brazil 
20 Nhandu vulpinus Brazilian South 
21 Phormictopus cancerides (F) 
Dominican Republic, 
Cuba, Haiti 
22 Pamphobeteus cf petersi Ecuador, Peru 
23 Psalmopoeus cambridgei (F) Trinidad and Tobago 
24 Psalmopoeus langenbucheri (F) Venezuela 
25 Psalmopoeus pulcher Panama 
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(F) 
26 Theraphosinae sp. (F) Chile 
 
2.3.7  Theraphosid venoms with no apparent effect on nAChRs  
 
Figure 2.7 summarizes FLIPR data obtained with venom from four American 
theraphosids (Aphonopelma crinitum, Avicularia sp., Homoeomma sp. and 
Pseudhapalopus sp.; Table 2.6). These venoms had only a minor effect on α3* 
nAChRs (Figure 2.7A) and no effect on α7 nAChRs (Figure 2.7B). 
 
 
Figure 2.7. Four tarantula venoms without potent modulators of α3* or α7 
nAChRs. 
Normalized FLIPR responses resulting from a screen of crude venom against 
human α3* (A) and α7 nAChRs (B). All venoms were tested at 2 µg/well. Each 
value corresponds to averages of normalized calcium responses over baseline 
of at least three independent experiments and with n = 3. For legend see table 
2.5. Dotted lines represent the control response in the absence of venoms. On 
graphic A and B, the control responses corresponds to stimulation of α3* with 
nicotine (30 µM), and α7 choline (30 µM), respectively. Using one-way ANOVA, 
the means between each venom and the control responses (nicotine response 
were compared. The number of (*) indicates the degree of significance at P < 
0.05 probability level. Those values that lack of significance do not have the 
symbol (*). 
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Table 2.6. Venoms from American theraphosids that lack of modulators of 
human α3* and α7 nAChRs. 
Theraphosid spider Geographic location 
Aphonopelma crinitum 
(F) 
Northern Mexico 
Avicularia sp. (F) 2 Bolivia-Rio Madre 
Homoeomma sp. (blue) Peru 
Pseudhapalopus sp. 
(F) 
South America 
 
 
 
2.3.8  Effect of non-theraphosid mygalomorph venom on vertebrate nAChRs 
 
Unfortunately, I only had access to one non-theraphosid mygalomorph venom for 
this study, namely Macrothele gigas from the family Hexathelidae (see condensed 
phylogenetic tree in Figure 2.8). M. gigas venom blocked both the α3* and α7 
nAChR subtypes. At 2 µg, M. gigas venom reduced the nicotine-evoked calcium 
response in the FLIPR assay by 28 ± 22% and the response evoked by choline in 
the presence of PNU-120596 by 46 ± 27%. 
 
2.3.9  Taxonomic distribution of nAChR modulators within Araneae  
 
Figure 2.8 summarizes the data obtained from the high-throughput FLIPR-based 
screen of spider venoms against human nAChRs. Figure 2.8A shows the 
distribution of blockers, agonists and inactive venoms within the infra-orders 
Mygalomorphae and Araneomorphae, while Figure 2.8B shows the distribution of 
nAChR modulators mapped onto a condensed phylogenetic tree of spiders (order 
Araneae).  
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Figure 2.8. Summarise of the high-throughput screening of spider venoms.  
(A) Pie charts summarising the different types of nAChR modulators found in 
the venoms of mygalomorph spiders and araneomorph spiders. (B) Distribution 
of nAChRs modulators found in spider venoms mapped onto a condensed 
phylogenetic tree. Circles to the right of the tree denoting biological activities 
are sized according to the dominance of that pharmacology in the venom. NS 
denotes "not sampled". 
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2.4  DISCUSSION 
 
Today, it is recognized that an imbalance of the cholinergic pathways in humans 
may lead to several pathologies (Picciotto, 2012). Therefore, nAChRs are now 
molecular targets; and several studies have been carrying out to understand their 
mechanisms of regulation, but few advances have been made (Bencherif, 2014; 
Pammolli, 2011; Russo, 2014). In the field of agronomy, invertebrate nAChRs are 
also targets of neonicotinoids that are used to control insect pests (Fischer, 2014; 
Matsuda, 2009); and these are one of the most successful classes of chemical 
insecticides ever developed, although it is no selective for insect pests, it has been 
found to be lethal to other insects of importance in agriculture such as pollinators 
(Moffat, 2015). Part of the problem is that many studies of cholinergic receptors 
are limited by the number and type of selective modulators for nAChRs (Bauwens, 
2015; Gotti, 2007).  
 
Since spiders are the most successful insect predators on the planet (for a review 
see (King and Hardy, 2013)), it would be surprising if they had not developed 
nAChR modulators as part of their venom arsenal. To date, however, there are 
very few reports of this pharmacological activity in spider venoms. We therefore 
decided to screen spider venoms for nAChR modulators. Since cloned insect 
nAChRs were not available, we performed screens against two subtypes of 
vertebrate nAChRs (α3* and α7) based on the hypothesis that nAChR modulators 
might also be useful for deterring vertebrate predators.  
 
Several high-throughput FLIPR screenings were carried out to identify “hit” 
venoms that were to contain promising lead compounds to further use as research 
tools, or lead drugs. However, the data indicated that most of the spider venoms 
contained predominantly blockers highly potent for subtype α3* nAChRs, and 
blockers for α7 nAChRs; and a non-selective modulator was not considered to 
isolate because adverse effects of some agents under current study are 
associated with low selectivity for cholinergic receptors (Kalayci, 2013; Koga, 
2014; Mihalak, 2006). Even when a toxin lead, which was expected not being 
acylpolyamine type but selective for either α3* or α7 nAChRs, was not identified, 
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the resulting data was suitable to further analyse the distribution of modulators 
across the phylogenetic tree of spiders. 
 
Because spiders are venomous animals with more than 45,000 extant species 
spread across 114 taxonomic families (see http://www.wsc.nmbe.ch/statistics/), it 
was impossible in this study to sample broadly across this immense phylogenetic 
tree, so we instead chose 71 species spread across the major suborder 
Opisthothelae, which is comprised of the infraorders Araneomorphae ("modern" 
spiders") and Mygalomorphae ("primitive spiders"). Note that Mesothelae, the 
other taxonomic suborder with Araneae, comprises only ~100 extant species that 
are thought to be non-venomous (for a review, see (Xu, 2015)).  
 
With the caveat that it is difficult to make firm conclusions in the absence of deeper 
taxonomic sampling across the phylogenetic tree, two trends emerge from the 
data summary shown in Figure 2.8; and the discussion is based on the trends:  
  
1) Although nAChR modulators can be found in distantly related species across 
the phylogenetic tree, they were absent from 3 of the 6 venoms that we sampled 
from the RTA clade as well as the single member of the family Austrochilidae that 
we sampled. In addition, the 3 left venoms from the RTA clade had a partial 
blocking effect on nAChRs. This indicates that modulation of vertebrate nAChRs 
was either a basal pharmacology in spider venoms that was secondarily lost in 
some species, or that it arose independently numerous times during Araneae 
evolution. Deeper phylogenetic sampling in combination with biochemical 
characterisation of the nAChR modulators found in spider venom will be required 
to discriminate between these possibilities. 
 
2) In this study, nAChR agonists, and specific blockers of the α3* subtype were 
only found in the venom of theraphosid spiders, the largest family of mygalomorph 
spiders with ~1000 species. Thus, mygalomorph venoms appear to be richer in 
nAChR modulators than araneomorph venoms. 
 
From the total of 71 spider venoms used in the present work, 12 belonged to 
spiders of the suborder Araneomorphae. The resulting data indicated that 
	   68 
modulators for vertebrate nAChRs have evolved differently that were leading by 
driven forces of natural selection such as geographical isolation and interactions 
between preys and predators (Morgenstern, 2011; Zelanis, 2012). Probably, the 
reason of absence of modulators in the venom of H. troglodytes is because it lives 
in caves and underground drainages (Doran, 2001), and it is unlikely to encounter 
vertebrate predators. Furthermore, they do not forage for insects instead they use 
their long webs up to 1 metre of diameter to trap insects such as cave crickets.  
 
The cheliceral structure of “modern” spiders evolved into an improved tool that can 
be moved sideways, unlike fangs from “primitive” spiders that are moved up and 
down 1. This feature in araneomorph spiders allows them grapping easily big preys 
such as small vertebrates without using their venoms (Nyffeler and Pusey, 2014). 
They attack their prey by crushing their fangs on the neck of preys that could be 
small fish and lizards (Nyffeler and Pusey, 2014). In contrast, in mygalomorph 
spiders, the position and movement of their cheliceraes do not allow 
mygalomorphs to hunt preys bigger than big insects. Instead, they preferentially 
use their venoms to immobilise them.  
 
We could hypothesise that appearance of strong, and robust cheliceraes that are 
moved sideways as forceps and the reduction of the length of “modern’ spiders 
could lead to reduce the synthesis of modulators for vertebrate nAChRs in spider 
venom. For instance, spider venoms with no potent blocking effect or no effect on 
nAChRs belonged to spiders from the phylogenetic branch RTA clade, although in 
the same phylogenetic clade, modulators for nAChRs could randomly appear on 
other species. It can be evidenced when no substantial blocking effect on nAChRs 
was observed in venoms from Ancylometes sp., V. sylvestriformis (Ctenidae), and 
the lack of no modulators in venom from H. jugulans (Sparassidae), while venom 
from Megadolomedes australianus contain potent blockers for nAChRs. The two 
ctenid spiders studied in this research work have strong and long fangs that may 
be used as defence. Moreover, they are found at night at the edge of water 
sources in remote areas of the forest or the jungle (Nyffeler and Pusey, 2014) 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Most information about the habitat, biology, and behaviour of spiders was obtained from web 
pages of The Australian Museum and http://www.arachne.org.au.. 	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where they may have few contact to humans. Interestingly, M. australianus have 
strong and large fangs and also potent blockers for vertebrate nAChRs. We could 
speculate that toxins against nAChRs allowed that the spider could prey on fish, 
which can be double of its size, tadpoles and insects (Nyffeler and Pusey, 2014). 
An important physical adaptation in the spider is the presence of long legs that can 
sense the vibrations of water when fish are nearby. Nevertheless, M. australianus 
is relatively large because the length of its legs; and it may cause being seen 
easily by natural enemies, and toxins against vertebrate nAChRs may be an 
advantage.  
 
Interestingly, our data showed that Araneomorph spiders from the araneoidea 
family produced venoms with potent antagonists for vertebrate α3* and α7 
nAChRs. For instance, two Australasian species of the genus Nephila, N. pilipes 
and N. plumites showed to have in their venoms blockers for both α3* and α7 
nAChRs. These compounds are likely to be acylpolyamines that have previously 
been reported in other Nephila species such as Nephila madagascariencis (for a 
review, see (Estrada, 2007)). Their preys are commonly insects, reviewed in 
(Harvey, 2007) that are caught in their webs; because they produce a very strong 
web between trees, on occasions small birds can get trap. Their natural enemies 
are small vertebrates such as hummibirds (Vollrath, 1985). It seems modulators 
against vertebrates could be evolved to protect themselves from them. Also, 
humans could be considered as predators. Some native tribes from villages and 
settlements from Thailand consider spiders of genus Nephila as food (for a review, 
see (Harvey, 2007). Sometimes N. pilipes is found in house gardens and N. 
plumipes can build their webs against buildings (for a review, see (Harvey, 2007)) 
and it makes these spiders more exposed to be grape from people; and it might 
explain why venoms from N. pilipes and N. plumites contain potent blockers for 
human nAChRs. 
 
Mygalomorphae or “primitive” spiders  
 
Because the suborder Mygalomorphae is considered an ancient monophyletic 
group (Coddington and Levi, 1991), and its oldest fossil was dated to the Triassic 
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(Selden and Gall, 1992), this phylogenetic group can be particularly useful to 
estimate the origin of modulators for vertebrate nAChRs. 
 
From the 71 spider species used to initially searching for lead compounds, 59 
venoms belonged to spiders of the suborder Mygalomorphae 2. The data showed 
that most of the venoms blocked both subtype of mammalian nAChRs, and it is 
likely the toxins were type acylpolyamines. Indeed the first acylpolyamine was 
discovered in theraphosid spiders (for a review, see (Estrada, 2007)).  
 
The only hexathelid species assayed herein was Macrothele gigas. Its venom 
contained blockers for vertebrate α3* and α7 nAChRs. It also might contain an 
agonist for α3* but an extra analysis of the active fraction may be carried out to 
confirm the agonistic effect. It is likely blockers type acylpolyamines existed in the 
venom of primitive spiders since the Triassic period because the ancestor of M. 
gigas has been estimated to appear on that era. Interestingly, venoms from 
Hexathelidae and Mygalomoprhae contain agonists and antagonists. This 
similarity is not surprising because hexathelid and mygalomorph spiders are 
closely related. It also suggests that a common ancestor could contain modulators 
for vertebrate nAChRs in its venom. They are typically much larger than 
araneomorphs, and they are consequently more prone to predation from 
vertebrate predators such as birds, rodents and small reptiles. 
 
On the other hand, a potential agonistic activity on nAChR was detected in venom 
from Haplopelma hainanum. This spider lives in burrows that can reach up to 1 
meter of depth. Its venom is categorized as highly venomous. The data herein 
indicates this venom is likely to contain an agonistic component for nAChRs. 
Probably, native acetylcholine may be present in the venom in large amounts 
because there is a report of small molecules of a related species. For example, in 
the venom of Haplopelma lividum was detected the polyamine spermine, 
histamine, adenosine; and glutamic acid that was abundant in the venom fraction 
of low molecular weight molecules (Moore, 2009). The plasticity of toxins to evolve 
in accordance to environmental pressures, such as type of prey and type of 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  The data is summarised in Figure 2.8.	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predators have been reported recently in the venom of Haplopelma hainanum 
(Zhang, 2015b). It was shown that its intraspecific venom variations of blockers for 
vertebrate nAChRs could be attributed to interaction gene-environment. In 
addition, the presence of agonist for α7 nAChRs in venoms from Pamphobeteus 
sp., Sericoplema rubronites and Xenesthis sp. remain to be confirmed. These 
tarantulas are usually trade as pets; and if the presence of agonists for α7 
nAChRs is due to the constant interaction with humans when these are in captivity 
need to be evaluated. It would be interesting to further study venoms from these 
tarantulas that naturally inhabit in the forest and the Amazon in South America.  
 
According to the results of the present thesis, spider venoms from the family 
theraphosidae, such as Selenocosmia crassipes, Selenocosmia effera, 
Selenocosmia sp (Papua New Guinea), Coremiocnemis tropix, Selenotholus 
foelschei contain potent toxins that block preferentially human neuronal α3* 
nAChRs. In Australia, Selenocosmia sp. is known to cause severe pain in humans 
and death in canines while venoms from Coremiocnemis tropix (spread out in 
North Australia) and Selenotholus foelschei (inhabit only in Western Australia) are 
shown to have a pre synaptic action at the neuromuscular junction in chicks 
(Herzig, 2008). The analysis of our data indicates that these venoms may contain 
compounds that preferentially act on the autonomic nervous system where the 
“ganglionic” nAChR subtypes are expressed, and mediate the pain observed in 
people bite by these spiders instead of targeting the nAChR muscle subtype. 
 
On the other hand, theraphosid spiders from the new world studied herein showed 
to contain blockers for vertebrate cholinergic receptors. Scarcely information is 
available about venomic, diet and habitat of spiders from the new world, although, 
some works have been carried out in some spiders assayed in this work (Bertani 
and Fukushima, 2009).  
 
In this study, the data showed that venom from Aphonopelma crinitum had some 
blocking effect on α3* nAChRs but it was not significant. The presence of 
acylpolyamines cannot be discarded because in a previous work two 
acylpolyamines were discovered in the venom of Aphonopelma chalcodes 
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(Skinner, 1990). Aphonopelma crinitum, Pseudhapalopus sp. and Homoeomma 
sp. may produce few blockers for α3* nAChRs with no effect on α7 nAChRs 
because these are found in remote areas where there is little human activity . For 
example, Aphonopelma crinitum lives in dry areas or desserts of North Mexico. 
 
The plasticity of toxins to evolve in accordance to environmental pressures have 
been reported recently in venoms of several species from Avicularia sp., 
Grammostola, sp., Holothele sp., Nhandu sp., and Psalmopoeus sp. (Zhang, 
2015b). The diversity of antagonists for vertebrate nAChRs could be attributed to 
interaction gene-environment. The Spiders Euathlus sp. and Thrixopelma sp. 
inhabit along the western coast of Chile, and Thrixopelma cyaneolum inhabit the 
coast along western Peru, all seemed to contain blockers for the subtype α3* 
nAChRs. However, one venom was extracted from a Grammostola grossa species 
that inhabits the Eastern Coast of Argentina. Its venom also had a blocking effect 
on the subtype α3* nAChRs but the presence of modulators in its venom cannot 
be attributed to the type of prey or predators that are found on the geographical 
place where this species inhabits (the coast). G. grossa may be the same group of 
spiders that originally inhabit the Amazons in Brazil that are spread around 
adjacent regions of Brazil. At some point Grammostola species could evolved into 
other specie that produce blockers for both subtypes of α3* and α7 nAChRs. This 
is the case for Grammosotla rosea that is found in Bolivia, then, there could be a 
spread of this species heading down to south America like the case of 
Grammostola iheringi and Grammostola porteri that can be found in Chile and 
Argentina. In general, few research are carried out about tarantula venoms, in 
particular for those species found in Brazil, such as Acanthoscurria paulensis 
(Mourão, 2013). Arboreal species Avicularia genus consist of 13 species and 
these are found in Central and South America. Scarce studies about venoms from 
Avicularia juruensis exist in the scientific literature (Ayroza, 2012). Avicularia 
species are threatened for severe deforestation in the rainforest in Brazil and the 
illegal trade to collectors (Bertani and Fukushima, 2009). It could explain why 
several species of Avicularia has been spread across other regions around Brazil. 
Interestingly, all species studied herein that are found in Brazil (in the forests of the 
Amazonas) contain blockers for α3* nAChRs. 
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The two tarantulas Holothele sp. were collected originally from Colombia and 
Peru. Their venoms contain blockers for both subtype nAChRs. Probably both 
species are the same and these were spread around Colombia and northern Peru. 
These tarantulas live in burrows, and blockers for cholinergic receptors could be 
used for protection against small vertebrate predators. Like Holothele sp., the 
theraphosid Nhandu vulpinus, Nhandu tripepii and Nhandu chromatus live in 
burrows in the savannahs and tropical forests of South Brazil. Their venoms have 
low toxicity and could be comparable to bee sting. Their diet is based on crickets, 
mealworms and houseflies. It is likely the blocking effect on nAChRs is for 
protection against small predators. 
 
It is known from previous studies that nicotinic receptors are densely expressed in 
insects and these share similar pharmacological profiles to counterparts 
expressed in vertebrates (Sattelle, 2005). It suggests that the effect observed in 
human nicotinic receptors caused by some spider venoms from the two major 
lineages Mygalomorphae and Araneomorphae could share some similitude to 
neuronal nicotinic cholinergic receptors from invertebrates, which known to be 
expressed in neurons and cell bodies in insects. It is likely that selective toxins for 
invertebrate nAChRs may be found because spiders based most of their diet on 
insects. 
 
The mechanisms of toxin evolution and diversity in spiders are currently not well 
understood (Zhang, 2015b), although, this thesis provides with important insights 
of the evolutionary role of toxins against mammalian cholinergic receptors. The 
number of different spider venoms used on the present thesis is small to make 
generalised conclusions. However, the results so far indicated that blockers for 
vertebrate cholinergic receptors were likely to be present in old ancestor of 
mygalomorph spiders. Inhibitors for human neuronal α3* and α7 nAChRs are the 
major compounds in “primitive” spiders. These are likely to be acylpolyamines that 
have previously been reported in “primitive” spiders (Skinner, 1990; Zhang, 
2015b); and it implies that acylpolyamines have existed about 400 million years 
ago, and are the simplest toxin to synthesise with high potency, unlike synthesis of 
peptides or proteins. Furthermore, the data suggests that modulators for 
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vertebrate nAChRs were decreased notoriously when araneomorph spiders 
appeared.  
 
Our data also implies that primitive spiders produce a wide range of modulators for 
vertebrate nAChRs that could include agonistic modulators on α7. It seems the 
large size of mygalomorph spiders and their cheliceral position to subdue their 
preys was no advantageous with the appearance of new vertebrate animals. It is 
likely that in “primitive” spiders the role of toxins for both subtypes of mammalian 
nAChRs is for defence. We could speculate also that in “modern” spiders 
synthesis of agonists for α7 is energetically more expensive than no selective 
antagonists for α3* and α7 nAChRs. After all, no selective blockers may lead to 
the same outcome that warns vertebrate predators away. 
 
To summarize, we can suggest that “modern” spiders (Araneopmorphae) 
appeared with new physical characteristics to adapt them to new ecosystems; and 
in parallel their venoms evolved with the appearance of different vertebrate 
species, including small mammals. Araneomorph spiders retain the presence of 
cheliceraes but it seems these were adapted to pinch the preys and avoid they 
scape, instead of rely on their venoms to immobilise their preys, like in the case of 
Mygalomorph spiders. 
 
The resulting data of this thesis is a started point to further selection of venoms 
with potential effect on cholinergic receptors of invertebrates. Extra screenings 
using the FLIPR system, and including as positive control neonicotinoids may help 
to choose “hit” venoms.  
 
This is the first study of distribution of toxins from spider venoms against human 
neuronal nAChRs, and it is hoped that it can serve to the discovery of novel toxins 
against invertebrates as well as help to reveal the evolutional process of spider 
toxins. 
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CHAPTER 3 — NACHR MODULATORS FROM SCORPION VENOM 
 
3.1  INTRODUCTION 
 
Like spiders, scorpion venoms contain a vast number of uncharacterized 
compounds, and therefore they represent an untapped source of novel toxins with 
potential applications in medicine, agronomy and as research tools (Harrison, 
2014; King, 2014; King and Coaker, 2014; Wu, 2014). It has been estimated that 
the molecules currently described from scorpion venoms represent less than 1% 
of all components predicted to be in their venoms (Quintero-Hernandez, 2013). 
Thus, we extended the search for modulators of vertebrate α7 and α3* nAChRs to 
five scorpion venoms. As outlined below, this work led to the isolation of a non-
selective agonist of α7 and α3* nAChRs, from the venom of the giant forest 
scorpion Heterometrus spinnifer. 
 
3.1.1  Scorpion toxins and their pharmacological action 
 
Scorpions (Arthropoda: Chelicerata: Arachnida: Scorpiones) use their venoms to 
immobilise prey and/or to defend against predators or competitors. The common 
biological function of these venoms is their action on a variety of voltage-gated ion 
channels in invertebrates and small vertebrates. In particular, scorpion venoms are 
rich in modulators of both insect and vertebrate voltage-gated sodium (for a 
review, see (Egea, 2015)) and Potassium (Kv) (Chugunov, 2013; Morales-Lázaro, 
2015; Quintero-Hernandez, 2013; Swartz, 2013). The most toxic scorpion venoms 
for mammals are from Androctonus sp. and Leirurus quinquestriatus (paleotropical 
especies) and Centruroides sp. and Tityus sp. (neotropical especies), and these 
venoms have been extensively studied due to their clinical relevance (DeBin, 
1993; Diaz, 2009; Kularatne and Senanayake, 2014; Quintero-Hernandez, 2013; 
Rjeibi, 2011). Most of the components purified and identified from scorpions to 
date are toxins that act on Nav (Forsyth, 2012; Meves, 1984; Zhu, 2012), Kv 
(Camargos, 2011; Nirthanan, 2005; Xie, 2012), Cav (Norton and McDonough, 
2008; Shahbazzadeh, 2007) and chloride channels (DeBin, 1993; Nie, 2012; 
Rjeibi, 2011; Zheng, 2000). In particular, toxins that target Nav channels that are 
largely responsible for the symptomatology of mammalian envenomation 
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(Caliskan, 2012; Clot-Faybesse, 2000; Quintero-Hernandez, 2013) and paralysis 
in insects (Billen, 2008; DeBin, 1993; Forsyth, 2012). However, the effect of 
scorpion venom on nAChRs has been scarcely documented. 
 
Androctonin, a disulphide-bridged peptide isolated from the hemolymph, but not 
the venom of Androctonus australis, shows some similarity to a nAChR named α-
conotoxin SII, but its effect on nAChRs has not been determined (Ehret-Sabatier, 
1996).  
 
A non-toxic venom extract from the scorpion Buthus occitanus tunetanus contains 
a component that depolarises muscle cells via an effect on nAChRs (Cheikh, 
2007), but the authors did not isolate the active component.  
 
Venoms from scorpions reported as non-threatening to humans have not been 
extensively studied. Interestingly, venom from the giant forest scorpion 
Heterometrus spinnifer was reported to contain high concentration of acetylcholine 
and norepinephrine (Nirthanan, 2002). The authors suggested that acetylcholine 
induces muscle contraction in rat nerve-smooth muscle preparations through 
activation of muscarinic receptors. However, all of the bioassays were carried out 
with a venom fraction that contained all molecules from the venom with molecular 
masses less than 3 kDa, and the activity was not compared with pure 
acetylcholine.  
 
From our previous screening of 71 arachnid venoms for searching modulators for 
nAChR using a high-throughput FLIPR calcium assay, we detected an agonistic 
activity elicited from crude venom of H. spinnifer. We continued further to isolate 
the “hit” toxin responsible for the activity because venom compounds seem to 
have promising applications in therapy (Nie, 2012; Yang, 2011) and likely in 
agronomy (Morales-Lázaro, 2015 #7), as mentioned before the venom is devoid of 
harm in humans (Kularatne and Senanayake, 2014) and has not been extensively 
studied due to the lack of clinical interest (Cheikh, 2007; Nirthanan, 2002). 
 
The agonistic compound was isolated, and identified as a choline ester, named 
senecioylcholine. It activates human neuronal nAChRs endogenously expressed 
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in SH-SY5Y cells and the synthetic form did not show insecticidal effect. It is 
known ester of choline occurs naturally (Erspamer and Glässer, 1957; Erspamer, 
1953; Florey, 1963; Keyl, 1957), and mainly purified from hypobranchial gland of 
gastropods (Keyl and Whittaker, 1958; Roseghini, 1996). Even when acetylcholine 
is a choline ester present in invertebrate nervous system (Florey, 1963), 
senecioylcholine has not been before identified in scorpion venoms. Few 
pharmacological studies have been done for senecioylcholine and its isomer 
named tygloylcholine (Roseghini, 1996). Furthermore, there are discrepancies on 
the function of choline ester in the venom of gastropods as mechanism of defence 
(Erspamer and Glässer, 1957; Roseghini, 1996) and in the correct identification of 
senecioylcholine or tygloylcholine (Baker and Duke, 1976, 1978).  
 
The toxicity of senecioylcholine reported in vertebrates (Roseghini, 1996) and its 
non-selective agonistic effect on human neuronal nAChRs suggest its role in the 
venom is highly for defence against small vertebrates. The discovery of 
senecioylcholine in the venom of a scorpion, which uses its chelae to subdue its 
preys, makes a significant contribution in the evolution of venom compounds as 
defensive weapons, and it is the first evidence of a convergent evolution between 
scorpions and molluscs. To provide with a complete base for future research 
works in interactions prey-predator and evolution, this study was extended up to 
the pharmacological characterization of senecioylcholine and its isomers 
tygloylcholine and angeloylcholine, which could be present in other arachnid 
venoms. 
 
3.2  METHODS 
 
We used the high-throughput FLIPR assay outlined in Chapter 2 to screen five 
scorpion venoms for modulators of vertebrate α7 and α3* nAChRs. For details of 
the procedures used to identify “hit” venoms and purify bioactive venom 
components see the Section 2.5 and 3.3.2, respectively. 
 
3.2.1  Figure 3.1 shows an example of the protocol as applied to scorpion 
venoms 
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Figure 3.1A, shows the fluorescent response obtained by stimulation of α3* 
nAChRs with nicotine, and inhibition of this response by d-tubocurarine. Figure 
3.1B shows that the calcium fluorescence response is evoked mainly by activation 
of α3* nAChRs, which was inhibited by d-tubocurarine, and this nicotine response 
is independent of activation of Nav channels. On Figure 3.1C is shown the 
fluorescent response evoked by crude venom from A. crassicauda, which induces 
a robust increase in fluorescence prior to the addition of nicotine. The venom-
induced increase in fluorescence was not substantially inhibited by d-tubocurarine 
(Figure 3.1D) but it was notably by TTX (Figure 3.1 E), a non-selective Nav 
channel inhibitor (Figure 3.1E), Thus, the robust increase in fluorescence induced 
by A. crassicauda venom is likely due to the presence of an agonist of Nav 
channels endogenously expressed in SH-SY5Y cells. 
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Figure 3.1. A. crassicauda venom can induce calcium responses elicited via 
activation of Nav channels.   
(A) Fluorescent responses elicited by stimulation of α3* nAChRs with nicotine, 
and inhibition of this response by d- tubocurarine. (B) The calcium fluorescent 
response observed is mediated mostly by activation of α3* nAChRs with 
nicotine (30 µM). The inhibitor for Nav channels, TTX, does not inhibit the 
calcium response. (C) Addition of crude venom (2 µg) from A. crassicauda 
elicited fluorescent response (black trace), prior to the activation of α3* nAChRs 
with nicotine (blue trace). The venom-induced increase in fluorescence was not 
substantially inhibited by d-tubocurarine (panel D) but it was significantly 
inhibited by 2 µM TTX (panel E).  
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3.2.2  Scorpion venoms 
 
Dr Volker Herzig kindly provided five scorpion venoms for screening against 
vertebrate α7 and α3* nAChRs. The list of scorpion species used in this study is 
given in Appendix I. 
 
3.2.3  Venom fractionation 
 
Crude scorpion venom (1 mg) was dissolved in 1 ml of 5% of buffer B (90% 
acetonitrile containing 0.05% TFA) and centrifuged at 5,000 g for 15 min at 4°C. 
After centrifugation, the supernatant was loaded onto a Phenomenex C18 reverse-
phase HPLC (RP-HPLC) column Jupiter 250 x 4.60 mm; 5 µm particle size; 300 Å 
pore size and fractionation performed using Shimadzu HPLC system. Venom 
fractionation was performed using a flow rate of 1 ml/min and the following 
gradient of Buffer B in Buffer A (Milli-Q water + 0.05% TFA): 0–5 min: 5% Buffer B; 
5–10 min: 5–20% Buffer B; 10–50 min: 20–40% Buffer B; 50–55 min: 40–80% 
Buffer B; 55–57 min: 80% Buffer B. 
 
The elution profile was recorded at 214 nm and 280 nm, and fractions were 
collected manually based on 214 nm absorbance. At the end of the fractionation 
the samples were frozen, lyophilized, dissolved in Milli-Q water, and stored at –
20°C until required. 
 
3.2.4  Discovery of a choline ester from the venom of H. spinnifer 
 
We isolated the active fraction from H. spinnifer venom using two chromatographic 
steps of purification using the FLIPR high-throughput calcium assay described in 
the previous section.  The active fraction from the initial venom fractionation using 
a Jupiter C18 RP-HPLC column was further fractionated on a Grace Discovery 
Science Vydac® 218TP C18 RP-HPLC column 250 x 4.60 mm; 5 µm particle size; 
and 300 Å pore size using a flow rate of 1 ml/min and the following gradient: 0–5 
min: 5% Buffer B; 5–10 min: 5–10% Buffer B; 10–50 min: 10–30% Buffer B; 50–55 
min: 30–80% Buffer B; 55–57 min: 80% Buffer B. 
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3.2.5  Determination of mass and purity 
 
The active component isolated from H. spinnifer venom was dissolved in 5% of 
acetonitrile (grade HPLC) and analysed via matrix-assisted laser 
desorption/ionization (MALDI) mass spectrometry (MS) performed on an Applied 
Biosystems mass spectrometer operating in the positive ion linear mode. The 
sample (0.4 µL) was mixed on a MALDI plate with 0.4 µl of a-cyano-4-
hydroxycinnamic acid (CHCA) matrix (6 mg/mL) dissolved in acetonitrile/ MilliQ 
water /formic Acid (50:45:5, v/v). 
 
The MALDI-TOF spectra did not reveal any masses higher than 1 kDa. Thus, the 
active fraction was further analysed via LCMS using an Agilent 1100 Series 
separations module equipped with diode array detector and Agilent 1100 Series 
LC/MSD mass detector in both positive and negative ion modes. The sample was 
run on an Agilent Zorbax-C8 column 4.6 mm x 150 mm, 5 µm particle size using a 
gradient of 10–100% methanol/H2O (with constant 0.05% formic acid modifier) 
over 15 min, using a flow rate of 1 mL/min. 
 
3.2.6  Identification of active compound using HRMS and LCMS 
 
High-resolution (HR) electrospray ionisation (ESI) MS measurements were 
obtained on a Bruker micrOTOF with an ESI probe by direct infusion in acetonitrile 
at 3 µL/min using sodium formate clusters as an internal calibrant. The active 
venom yielded m/z 186.1504 [M]+ (calculated for C10H20NO2, 186.1489). 
 
LC/MS was performed on native compound co-injected with synthetic choline 
esters using an Agilent 1100 series LC/MS with an Agilent Zorbax-C18 aqua 
column 4.6 x 150 mm, 5 µm particle size. Isocratic elution was performed using 
4% methanol/H2O (with constant 0.02% formic acid modifier) at a flow rate of 1 
mL/min, with single ion extraction at 186 [M+]. 
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3.2.7  Chemical synthesis of choline esters 
 
 
3.2.7.1  Synthesis of chlorocholine chloride 
 
 
Choline chloride (279 mg, 2 mmol) was dried under high vacuum at 200°C for 2 h. 
SOCl2 (2 mL) was added and the solution was heated under reflux for 1 h. After 
cooling, solvent was evaporated to dryness. Solid residue was redissolved in 
methanol (3 x 2 mL), and re-evaporated to dryness. The resultant white solid was 
dried under high vacuum at 80°C for 2 h. 
 
3.2.7.2  Synthesis of tigloylcholine 
 
 
 
To a solution of tiglic acid (200 mg, 2 mmol) in a dioxane–water (3:2) mixture (10 
mL), a solution of K2CO3 (138 mg, 1 mmol in water 10 mL) was added. After 
stirring for 10 min, the mixture was evaporated to dryness and again dried under 
high vacuum at 70 °C for 1 h. Chlorocholine chloride and anhydrous DMSO were 
added and the mixture heated at 60 °C for 48 h. DMSO was removed by vacuum 
distillation and the residue was purified by reverse phase column chromatography 
to afford tigloylcholine as a light brown hygroscopic solid. 1H NMR (600 MHz, 
CD3OD): δ 6.92 (qq, 7.1, 1.3 Hz, H-3), 4.59 (m, H2-2ʹ′), 3.75 (m, H2-1ʹ′), 3.22 (s, 
NMe3), 1.85 (dd, 1.3, 1.1 Hz, H3-5), 1.82 (dq, J = 7.1, 1.1 Hz, H3-4). 13C NMR (150 
MHz, CD3OD): δ 168.4 (C-1), 140.3 (C-3), 129.1 (C-2), 66.4 (C-2ʹ′), 59.1 (C-1ʹ′), 
54.60 (NMe), 54.58 (NMe), 54.55 (NMe), 14.6 (C-4), 12.3 (C-5). HRMS calc. for 
C10H20NO2+ 186.1489, found m/z = 186.1491. 
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3.2.7.3  Synthesis of senecioylcholine 
 
 
 
As described for the synthesis of tigloylcholine, starting with choline chloride (2 
mmol, 279 mg) and 2-methyl butenoic acid (2 mmol, 200 mg), senecioylcholine 
was synthesized and purified by reverse phase column chromatography, to afford 
senecioylcholine as a white hygroscopic solid. 1H NMR (600 MHz, CD3OD): δ 5.76 
(qq, 1.2, 1.2 Hz, H-2), 4.54 (m, H2-2ʹ′), 3.73 (m, H2-1ʹ′), 3.22 (s, NMe3), 2.18 (d, 1.2 
Hz, H3-4), 1.93 (d, 1.2 Hz, H3-5), 13C NMR (150 MHz, CD3OD): δ 166.8 (C-1), 
161.2 (C-3), 115.8 (C-2), 66.4 (C-2ʹ′), 58.1 (C-1ʹ′), 54.66 (NMe), 54.63 (NMe), 54.61 
(NMe), 27.6 (C-4), 20.6 (C-5). HRMS calc. for C10H20NO2+ 186.1489, found m/z  = 
186.1485. 
 
3.2.7.4  Synthesis of angeloylcholine 
 
 
 
As described for the synthesis of tigloylcholine, starting with choline chloride (2 
mmol, 279 mg) and angelic acid (2 mmol, 200 mg), angeloylcholine was 
synthesized and purified by reverse phase column chromatography, to afford 
angeloylcholine as a white hygroscopic solid. 1H NMR (600 MHz, δ 6.23 (qq, 7.2, 
1.3 Hz, H-3), 4.60 (m, H2-2ʹ′), 3.75 (m, H2-1ʹ′), 3.22 (s, NMe3), 2.00 (dq, 7.2, 1.3 Hz, 
H3-4), 1.91 (dq, J = 1.3, 1.3 Hz, H3-5). 13C NMR (150 MHz, CD3OD): δ 167.9 (C-1), 
141.7 (C-3), 128.0 (C-2), 66.4 (C-2ʹ′), 58.6 (C-1ʹ′), 54.59 (NMe), 54.56 (NMe), 54.54 
(NMe), 20.8 (C-4), 16.2 (C-5). HRMS calc. for C10H20NO2+ 186.1489, found m/z  = 
186.1483. 
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3.3  RESULTS 
 
3.3.1  High-throughput FLIPR assay 
 
To speed the venom-based discovery of “hit” biomolecules from five scorpion 
venoms a high-throughput FLIPR assay was performed (King, 2014; Vetter, 2011). 
Five venoms derived from scorpions of the family Buthidae were screened using 
the high-throughput FLIPR assay described in Chapter 2. At 2 µg, none of the 
venoms had a significant effect on vertebrate α7 or α3* nAChRs (Figure 3.2). 
However, crude venom (1 or 2 µg) from H. spinnifer elicited a transient calcium 
response that was potentiated by 50% in the presence of the positive allosteric 
modulator PNU-120596 (Figure 3.3A). This response was completely blocked by 
d-tubocurarine (Figure 3.3B) indicating that the venom activates neuronal 
nAChRs. The total elimination of the calcium response in the presence of PNU-
120596 by d-tubocurarine suggests that the agonistic effect observed is mediated 
totally by α3* and α7 nAChRs. Two other concentrations of venoms were tested at 
0.02 µg or at 0.2 µg (data not shown), and no effect was observed. The agonistic 
effect of this venom is therefore dose-dependent.  
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Figure 3.2. FLIPR screening of scorpion venoms against α7 and α3* 
nAChRs.   
1 µg of crude venoms from (A) L. quinquestriatus, (B) A. australis, (C) A. 
crassicauda, (D) G. grandidieri and (E) H. spinnifer was added to loaded- SH-
SY5Y cells in the presence of PNU-120596. Calcium responses were then 
measured for 300 s, followed by choline addition, and recording of calcium 
response for a further another 300 s. To show the participation of cholinergic 
receptors in the calcium responses following venom addition, the cells were 
treated by d-tubocurarine before starting the assay. There was no effect of d-
tubocurarine in the responses caused by venom from (A) L. quinquestriatus (trace 
in dashed lines and orange colour), (B) A. australis (trace in dashed lines and dark 
blue colour), and (C) A. crassicauda (trace in red colour). However, d-tubocurarine 
caused significant inhibition of the calcium response elicited by venoms from (D) 
G. grandidieri (trace in dashed lines and black colour) and (E) H. spinnifer (trace in 
blue colour). Traces are the average of at least three wells. 
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Figure 3.3. Non-selective activation of α7 and α3* nAChRs expressed in SH-
SY5Y by crude venom from H. spinnifer.   
(A) 2 µg of crude venom from H. spinnifer induced an increase of intracellular 
calcium in SH-SY5Y cells (blue trace) that was potentiated by PNU-120596 (red 
trace). (B) The calcium response elicited by 1 µg of crude venom from H. spinnifer 
in the presence of PNU-120596 (red trace) was totally blocked by d-tubocurarine 
(black trace in black colour). Traces are the average of at least three wells. 
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3.3.2  Isolation of the active compound from H. spinnifer venom 
 
1 mg of crude venom from H. spinnifer was separated by RP-HPLC (Figure 3.4) 
and fractions were manually collected. Each resulting fraction at 0.42 µg of total 
crude venom was evaluated using the FLIPR assay to evaluate its impact on 
activation of nAChRs using nicotine or choline plus the positive allosteric 
modulator PNU-120596 to stimulate the heteromeric subtypes α3β2/α3β4 and the 
homomeric subtype α7 nAChR, respectively. Only fraction 10, which eluted at 
9.49% acetonitrile in the C18 RP-HPLC separation (inset, Figure 3.4), activated 
the α3* subtype as its activity was substantially inhibited  (66%) by d-tubocurarine 
(30 µM) (Figure 3.5). Furthermore, the increased response in the presence of 
PNU-120596 (Figure 3.5) indicates that α7 nAChRs are also activated by fraction 
10. Thus, fraction 10 contains the agonistic molecule that is responsible for the 
calcium response elicited by crude H. spinnifer venom.  
 
 
 
Figure 3.4. HPLC fractionation of crude venom from H. spinnifer. 
Chromatogram resulting from fractionation of crude venom via C18 RP-
HPLC.   
The fraction highlighted in black (F10) activated α7 and α3* nAChRs in the FLIPR 
assay. The inset shows an expansion of the region containing F10, which eluted at 
∼ 13.6 min. 
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Figure 3.5. Activity of F10 from fractionation of crude venom from H. 
spinnifer.  
Active fraction 10 (F10) (1% from initial fractionation of 1 mg of crude venom) was 
assayed against vertebrate nAChRs using the FLIPR. F10 induced a maximum 
fluorescent response similar to that evoked by nicotine. The response was 
inhibited by d-tubocurarine and potentiated by PNU-120596. The difference are 
significant with a P < 0.05. One-way ANOVA was used to compare the means of 
each experimental treatment in relation to the control response (nicotine 
response). The values are averages of three independent experiments with n = 3. 
Dotted lines represent the control response in the absence of venoms. 
 
 
Fraction 10 (72 µg) was further fractionated using an analytical RP-HPLC 
(GRACE-Vydac C18 column RP-HPLC) (Figure 3.6) and the resulting fractions 
collected manually. Each of the active fractions were then analysed using the 
FLIPR assay, for activity against vertebrate nAChRs. Only two fractions were 
active in the FLIPR assay, which eluted at 11.1 min (fraction 4) and 13.6 min 
(fraction 7) (Figure 3.6). Unfortunately, further study of fraction 7 was not possible 
due to its low abundance as evidenced by its very low absorbance at 214 nm. 
Thus, further studies focused on fraction 4. Assay of fraction 4 (77.35 µM) in the 
FLIPR assay revealed that it induced a fluorescent response that was completely 
inhibited by 30 µM d-tubocurarine and potentiated by 10 µM PNU-120596 (Figure 
3.7). We therefore focussed attention on identification of the active component in 
this fraction.   
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Figure 3.6. Purification of the “hit’ toxin by RP-HPLC.  
Chromatogram resulting from separation of fraction 10 (72 µg) on an analytical 
C18 RP-HPLC. The “hit” toxin (fraction 4) eluted at 11.1 min (10.35% Buffer B), 
and fraction 7 eluted at 13.6 min (12.9% Buffer B). 
 
 
Figure 3.7. Agonistic activity of the “hit” toxin. 
Fraction 4 (77 µM) from analytical HPLC induced a fluorescent response that was 
totally blocked by d-tubocurarine and by PNU-120596. This suggests that fraction 
4 contains the “hit” toxin that is primarily responsible for the non-selective agonism 
of α3* and α7 nAChRs by H. spinnifer venom. The difference are significant with a 
P < 0.05. One-way ANOVA was used to compare the means of each experimental 
treatment in relation to the control response (nicotine response). The values are 
averages of three independent experiments with n = 3. Dotted lines represent the 
control response in the absence of venoms. 
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3.3.3  Identification of the active compound by high-resolution mass 
spectrometry 
 
Analysis of fraction 4 using MALDI-TOF-MS revealed no masses larger than 1 
kDa; it is difficult to detect masses smaller than this via MALDI-TOF-MS due to the 
noise caused by the matrix (CHCA). Thus, the sample was further analysed using 
HR-MS; this revealed a single compound with m/z 186.1489. Database searching 
revealed that the mass formula of C10H20N1O2 corresponds to a previously 
described choline ester named senecioylcholine (Keyl, 1957; Roseghini, 1996; 
Whittaker, 1960). However, there are two isomers of senecioylcholine, 
tigloylcholine and angeloylcholine, with identical mass formula and it is impossible 
to determine, which of these isomers corresponds to the native venom-derived 
compound based on HR-MS data alone. Thus, all three isomers were chemical 
synthesized and LC-MS co-elution studies were performed to identify the native 
compound. As shown in Figure 3.8, senecioylcholine but neither of the two 
isomers, co-elutes with the active nAChR agonist purified from H. spinnifer venom. 
Thus, we conclude that the α3*/α7 nAChR agonist in H. spinnifer venom is 
senecioylcholine. 
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Figure 3.8. Co-elution of bioactive compound from H. spinnifer venom and 
synthetic choline esters.  
LC-MS chromatograms of synthetic choline esters (top three panels), the α3*/α7 
nAChR agonist from H. spinnifer venom (bottom panel). LC was performed using a 
Zorbax C18-aqua column (4.6 × 150 mm), 5 µm particle size with a gradient of 
methanol + 0.02% formic acid at a flow rate of 1 ml/min.  
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3.4  DISCUSSION 
 
H. spinnifer is a scorpion from the  Scorpionidae family. It is widely distributed in 
South-eastern Asia but its venom has been poorly studied due to its innocuous 
effect on humans. However, it is still a rich source of mostly uncharacterised 
compounds that could be useful as novel modulators of nAChRs with clinical or 
agronomic relevance. In this study, we used activity-guided fractionation to isolate 
a novel agonist of vertebrate nAChRs from the venom of H. spinnifer. By using 
HR-MS in combination with chemical synthesis, we identified this agonist as 
senecioylcholine, a choline ester. We found that senecioylcholine is a non-
selective agonist of both α3β2/α3β4 and α7 nAChR subtypes endogenously 
expressed in SH-SY5Y cells.  
 
Choline esters are secreted by the hypobranchial gland of predatory marine 
gastropods from the family Muricidae (phylum Mollusca), for a review, see 
(Benkendorff, 2013) where they are postulated to play a role in predation and/or 
defence against predators. They have also been detected in the ventral nerve cord 
of the American lobster Homarus americanus (phylum Arthropoda, class 
Crustacea) (Keyl, 1957). The main choline ester identified in Mollusks is murexine 
(Erspamer and Glässer, 1957) although senecioylcholine has also been detected 
in significant quantities in the hypobranchial gland of Dicathais orbita. A more 
recent study identified tigloylcholine, an isomer of senecioylcholine, muricids of the 
genus Thais (Shiomi, 1998). Murexine and tigloylcholine are both lethal to mice, 
with intravenous administration leading to LD50 values of 8.5 mg/kg and 0.92 
mg/kg (Shiomi, 1998), respectively, for a review, see (Benkendorff, 2013). Like 
murexine, senecioylcholine is also a neuromuscular blocking compound with 
nicotine action on vertebrates (Roseghini, 1996). Interestingly, however, even high 
doses of senecioylcholine have no effect on the fruit fly Drosophila melanogaster 
(data not shown). Thus, it is likely that senecioylcholine is used by H. spinnifer for 
defence against vertebrate predators.  
 
A few bioactive compounds have previously been isolated from H. spinnifer venom 
k-KTx1.3, a non-toxic peptidic modulator of Kv channels (Nirthanan, 2005), and six 
novel antimicrobial peptides (Nie, 2012; Wu, 2014). H. spinnifer venom was also 
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shown to contain high concentrations of acetylcholine (∼80 µM) and this was 
proposed to be responsible for the reversible venom-evoked contracture of chick 
biventer cervicis muscle that was blocked by d-tubocurarine (Nirthanan, 2002). 
However, all the bioassays were carried out using a venom fraction that contained 
all molecules with molecular masses less than 3 kDa. Thus, it is likely that 
senecioylcholine, which was identified in H. spinnifer venom in the current study, 
mighty be at least partially responsible for the observed contracture of chick 
biventer cervicis muscle. The discovery of senecioylcholine in both scorpion 
venom (phylum Arthropoda) and predatory marine gastropods (phylum Mollusca) 
suggests that these phylogenetically unrelated organisms have convergently 
evolved the use of choline esters to defend themselves against vertebrate 
predators. It remains to be seen whether choline esters are ubiquitous in scorpion 
venoms or restricted to specific families or genera. However, the fact that only 2 of 
the scorpion venoms tested in this study appear to contain agonists of human 
α3β2/α3β4 and α7 nAChRs suggests that senecioylcholine and related choline 
esters are not widely distributed in scorpion venoms. 
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CHAPTER 4 — CONCLUSIONS 
 
Venomous animals use their venom to hunt preys and/or protect themselves 
against predators or competitors (Olsen, 2011). Arachnid venoms are complex 
mixtures of salts, small organic molecules, peptides and proteins that target a wide 
range of neuronal receptors and ion channels (Billen, 2008; Estrada, 2007; 
Morales-Lázaro, 2015; Quintero-Hernandez, 2013). A large number of modulators 
of voltage-gated ion channels have been isolated from the venom of spiders and 
scorpions, but there are very few reports of arachnid venom components 
modulating the activity of nAChRs. This is surprising given that neonicotinoid 
insecticides are one of the most successful classes of chemical insecticides, which 
suggests that targeting of insect nAChRs would be a useful pharmacology for 
arachnid venoms. Thus, the present work was carried out to survey the prevalence 
of nAChR modulators in arachnid venoms.  
 
Until recently, most characterizations of arachnid venoms used traditional 
biological assays that require large amounts of venom or venom fraction, which 
hampered studies of small venomous animals such as arachnids. In the current 
study we used a high-throughput FLIPR assay that enabled screens to be rapidly 
performed against human α3* and α7 nAChRs using only a few micrograms of 
venom. This approach allowed simultaneous screening of 76 arachnid venoms at 
four different concentrations. 
 
The data were reproducible even when different pools of venoms were used. This 
suggests that nAChR modulators in arachnid venoms are maintained even when 
they are kept in captivity. Our data revealed that spider venoms are a rich source 
of nAChR modulators, and that at least some scorpion venoms contain choline 
esters that agonize vertebrate nAChRs.  
 
We propose that these nAChR modulators are primarily used for defence against 
vertebrate predators. It would be of great interest in future to perform high-
throughput screens of arachnid venoms against insect nAChRs. Predation of 
insects is the primary role of arachnid venoms and therefore we might expect to 
find an even greater abundance and variety of compounds in these venoms that 
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modulate the activity of invertebrate nAChRs. Nevertheless, the current results 
strongly support the view that arachnid venoms are a novel source of modulators 
of ligand-gated ion channels with potential biotechnological applications.  
 
SUMMARY AND FUTURE DIRECTIONS 
 
The current work revealed, for the first time, that many spider venoms (65 of 71 
tested in this study) contain modulators of vertebrate nAChRs. Moreover, 31 of the 
65 active venoms contained non-selective modulators that affected both α3* and 
α7 nAChRs, whereas a smaller number (25) were selective modulators of 
vertebrate α3* nAChRs. This suggests that during the course of evolution, non-
selective modulators of vertebrate nAChRs were selected for the purposes of 
defence against vertebrate predators. However, future studies aimed at screening 
a taxonomically broader range of spiders against a larger panel of vertebrate 
nAChR subtypes will be required to address this hypothesis.  
 
The current study also identified a non-selective agonist of vertebrate nAChRs in 
the venom of the giant forest scorpion Heterometrus spinnifer (Scorpionidae). In 
contrast with most channel modulators found in arachnid venoms, this nAChR 
modulator was identified as senecioylcholine, a choline ester. Senecioylcholine 
was previously identified in the hypobranchial gland of some predatory marine 
gastropods (family Muricidae) but this is the first report of it being present in 
scorpion venom. H. spinnifer is one of the largest scorpion species but its venom 
is no lethal to humans. However, envenomation of humans by H. spinnifer leads to 
intense pain and inflammation, and senecioycholine may contribute to these 
symptoms. Thus, this study provides the first evidence for convergent evolution of 
a non-peptide toxin directed against vertebrate nAChRs. It would be interesting in 
future studies to examine whether senecioylcholine and related choline ester are 
found more broadly in scorpion venoms, particularly in species that are not 
relevant in clinic. 
 
While the current study focussed on vertebrate nAChRs, it would be of great 
interest in future to examine whether arachnid venoms also target nAChR 
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subtypes found in their major prey, namely insects. Compounds that specifically 
targeted insect, but not vertebrate, nAChRs would be of significant interest as 
bioinsecticide leads. In this respect, it might therefore be interesting to examine 
venoms that were shown in this study to be inactive against vertebrate nAChRs, 
such as those from the araneomorph spider Heteropoda jugulans and the 
mygalomorph spider Aphonopelma crinitum.  
 
Most venom research to date has focussed on animals of medical relevance, but 
this study has highlighted the value of studying venoms with non-lethal effects on 
humans when searching for novel compounds. The continued development of 
high-throughput screening methods and analytical tools that require only small 
amounts of venom will provide more opportunities in future for exploring the vast 
pharmacological repertoire encoded within the venoms of small venomous animals 
such as spiders and scorpions.  
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APPENDIX I 
 
Table I. List of spiders whose venoms were used in this work 
Araneomorphae (“modern” spiders) 
 Abbreviations 
No effect on α3* and α7 nAChR  
Austrochiloidea family  
1. Hickmania troglodytes H. troglodytes 
Blocking effect on α3* nAChR  
Araneoidea family  
2. Cyrtophora moluccensis C. moluccensis 
Blocking effect on α3* and α7 
nAChR 
 
Araneoidea family  
3. Eriophora transmarina E. transmarina 
Genus Nephila  
4. Nephila pilipes N. pilipes 
5. Nephila plumipes N. plumites 
No effect on α3* and α7 nAChR  
RTA Clade  
Superfamily Ctenoidea  
6. Ancylometes sp. Ancylometes sp. 
7. Viridasius sp. (sylvestriformis) Viridasius sp. 
Sparassidae family   
8. Heteropoda jugulans H. jugulans 
Partial blocking effect on α3* and α7 nAChR 
RTA Clade  
Superfamily Lycosoidea   
9. Lycosidae sp.  Lycosidae sp. 
Sparassidae family  
10. Sparassidae sp. 1 Sparassidae sp. 1 
11. Sparassidae sp. 2 Sparassidae sp. 2 
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Blocking effect on α3* and α7 
nAChR 
 
RTA Clade  
Pisauridae family  
12. Megadolomedes  M. australianus 
Mygalomorphae (“primitive” spiders) 
 Abbreviations 
Blocking effect on neuronal α3* 
and α7 nAChR 
 
1. Macrothele gigas M. gigas 
2. Acanthoscurria cf insubtilis A. insubtilis 
3. Ceratogyrus bechunanicus C. bechunanicus 
4. Ceratogyrus marshalli C. marshalli 
5. Ceratogyrus ezendami C. ezendami 
6. Eupalaestrus campestratus E. campestratus 
7. Ephebopus uatuman   E. uatuman 
8. Chilobrachys sp. 2 Chilobrachys sp. 2 
9. Grammostola porteri G. porteri 
10. Grammostola rosea G. rosea 
11. Grammostola sp. (Chilean 
North) 
Grammostola sp. 1 
12. Grammostola sp. (Concepcion, 
Chile) 
Grammostola sp. 2 
13. Grammostola sp. (Maule River, 
Chile) 
Grammostola sp. 3 
14. Holothele sp. (Carabobo, 
Colombia) 
Holothele sp. 1 
15. Holothele sp. (Peru) Holothele sp. 2 
16. Idiothele nigrofulva I. nigrofulva 
17. Lasiodorides striatus L. striatus 
18. Lasiodora striatipes L. striatipes 
19. Nhandu chromatus N. chromatus 
20. Nhandu tripepii N. tripepii 
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21. Nhandu vulpinus N. vulpinus 
22. Phormictopus cancerides P. cancerides 
23. Pamphobeteus cf petersi Pamphobeteus cf petersi 
24. Psalmopoeus cambridgei P. cambridgei 
25. Psalmopoeus pulcher P. pulcher 
26. Psalmopoeus langenbucheri P. langenbucheri 
27. Theraphosinae sp. (Chile) Theraphosinae sp. 
Potent blocking effect on α3* 
nAChR 
 
28. Avicularia metallica A. metallica 
29. Avicularia ulrichea A. ulrichea 
30. Avicularia sp. (Amazonas 
Purple, Peru) 
Avicularia sp. 1 
31. Coremiocnemis tropix C. tropix 
32. Chilobrachys sp. (Penang, 
Malaysia) 
Chilobrachys sp. 1 
33. Euathlus sp. (green, chile) Euathlus sp. 1 
34. Euathlus sp. (“red”=”fire”, 
Chile) 
Euathlus sp. 2 
35. Euathlus vulpinus (crème, 
Chile highland) 
E. vulpinus 
36. Grammostola grossa G. grossa 
37. Grammostola iheringi G. iheringi 
38. Orphnaecus philippinus O. philippinus 
39. Orphnaecus sp. (‘treedweller’, 
Paqnai-Island, Phillippines) 
Orphnaecus sp. 
40. Paraphysa scrofa P. scrofa 
41. Pelinobius muticus P. muticus 
42. Poecilotheria striatus P. striatus 
43. Pterinochilus murinus P. murinus 
44. Selenocosmia crassipes S. crassipes 
45. Selenocosmia effera S. effera 
46. Selenocosmia sp. (Papua Selenocosmia sp. 1 
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New-Guinea) 
47. Selenocosmia sp. Selenocosmia sp. 2 
48. Selenotholus foelschei S. foelschei 
49. Thrixopelma cyaneolum 
(PERU) 
T. cyaneolum 
50. Thrixopelma sp. (Chile) Thrixopelma sp.  
51. Thrixopelma lagunas sp. 
(Peru) 
T. lagunas  
Potential agonistic effect on α7 nAChR. Further analysis is required to 
confirm the venom effect on subtype α7.  
52. Haplopelma hainanum H. hainanum 
53. Pamphobeteus sp. 
(platyomma) 
Pamphobeteus sp. 
54. Sericopelma rubronites S. rubronites 
55. Xenesthis sp. (‘white’, 
Colombia) 
Xenesthis sp. 
No effect on α3* and α7 nAChR 
56. Aphonopelma crinitum A. crinitum 
57. Avicularia sp. (Rio Madre, 
Bolivia) 
Avicularia sp. 2 
58. Homoeomma sp. (blue) Homoeomma sp. 
59. Pseudhapalopus sp. 
(langhaarig) 
Pseudhapalopus sp. 
 
 
Table II. List of scorpions whose venoms were used in this work 
Abbreviations 
Buthidae family 
1. Androctonus australis A. australis 
2. Androctonus crassicauda A. crassicauda 
3. Leirurus quinquestriatus L. quinquestriatus 
4. Grosphus grandidieri G. grandidieri 
Scorpionidae family 
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Agonistic effect on α3* and α7 
nAChR 
 
1. Heterometrus spinnifer H. spinnifer 
 
 
